FILED PURSUANT TO RULE 424(B)(5) |
REGISTRATION NO. 333-266704 |
PROSPECTUS SUPPLEMENT |
(TO PROSPECTUS DATED AUGUST 15, 2022) |
SOPHiA GENETICS SA
Up to $50,000,000
Ordinary Shares
We have entered into a sales agreement with Cowen and Company, LLC (the
“sales agent”), dated August 8, 2023, relating to the sale of our ordinary shares, par value CHF 0.05 per share, offered by
this prospectus supplement and the accompanying prospectus (such agreement, the “sales agreement”). In accordance with the
terms of the sales agreement, under this prospectus supplement, we may offer and sell our ordinary shares having an aggregate offering
price of up to $50,000,000 from time to time through the sales agent.
Sales of our ordinary shares, if any, under this prospectus supplement
will be made by any method permitted that is deemed an “at the market offering” as defined in Rule 415(a)(4) under the Securities
Act of 1933, as amended (the “Securities Act”). The sales agent is not required to sell any specific amount, but will act
as our sales agent using commercially reasonable efforts consistent with its normal trading and sales practices. There is no arrangement
for funds to be received in an escrow, trust or similar arrangement.
The sales agent will be entitled to compensation at a commission rate
of up to 3.0% of the gross sales price of any ordinary shares sold under the sales agreement. In connection with the sale of ordinary
shares on our behalf, the sales agent will be deemed to be an “underwriter” within the meaning of the Securities Act and the
compensation of the sales agent will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification
and contribution to the sales agent with respect to certain liabilities, including civil liabilities under the Securities Act. See “Plan
of Distribution” beginning on page S-42 for additional information regarding the compensation to be paid to the sales agent.
Our ordinary shares are listed on the Nasdaq Global Select Market (“Nasdaq”)
under the symbol “SOPH.” On August 4, 2023, the last reported sale price of our ordinary shares on Nasdaq was $3.64 per share.
We are an “emerging growth company” as defined under U.S.
federal securities laws and, as such, elect to comply with reduced public company reporting requirements. See “Prospectus Supplement
Summary—Implications of Being an Emerging Growth Company and Foreign Private Issuer.”
Investing in our securities involves a high degree of risk. See the
“Risk Factors” section beginning on page S-7 of this prospectus supplement and any risk factors in our Securities and
Exchange Commission (“SEC”) filings that are incorporated by reference in this prospectus supplement.
Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus
is truthful or complete. Any representation to the contrary is a criminal offense.
TD Cowen
Prospectus supplement dated August 8, 2023.
TABLE OF CONTENTS
PROSPECTUS SUPPLEMENT
PROSPECTUS
ABOUT THIS PROSPECTUS SUPPLEMENT
This document consists of two parts. The first part is this prospectus
supplement, which describes the specific terms of this offering. The second part is the accompanying prospectus, which is part of a registration
statement that we filed with the SEC using a “shelf” registration process. The accompanying prospectus provides you with a
general description of the securities that may be offered by us, some of which may not apply to this offering. This prospectus supplement
and the information incorporated by reference in this prospectus supplement adds to, updates and, where applicable, modifies and supersedes
information contained or incorporated by reference in the accompanying prospectus.
Before buying any of the securities that we are offering, you should
carefully read both this prospectus supplement and the accompanying prospectus with all of the information incorporated by reference in
this prospectus supplement, as well as the additional information described under the heading “Where You Can Find More Information”
and “Information Incorporated by Reference.” These documents contain important information that you should consider when making
your investment decision. We have filed or incorporated by reference exhibits to the registration statement of which the accompanying
prospectus forms a part. You should read the exhibits carefully for provisions that may be important to you.
To the extent there is a conflict between the information contained
in this prospectus supplement, on the one hand, and the information contained in the accompanying prospectus or in any document incorporated
by reference in this prospectus supplement, on the other hand, you should rely on the information in this prospectus supplement, provided
that if any statement in one of these documents is inconsistent with a statement in another document having a later date—for example,
a document incorporated by reference in this prospectus supplement—the statement in the document having the later date modifies
or supersedes the earlier statement.
The information contained in this prospectus supplement, the accompanying
prospectus or any document incorporated by reference in this prospectus supplement is accurate only as of their respective dates, regardless
of the time of delivery of this prospectus, the accompanying prospectus or the documents incorporated by reference in this prospectus
or in the accompanying prospectus or the sale of any securities. Our business, financial condition, results of operations and prospects
may have changed materially since those dates.
Neither we nor the sales agent have authorized anyone to provide you
with information that is different from that contained in this prospectus supplement, the accompanying prospectus, or any free writing
prospectus we may authorize to be delivered or made available to you. Neither we nor the sales agent take responsibility for, or provide
assurance as to the reliability of, any other information that others may give you. This prospectus supplement does not constitute an
offer to sell or the solicitation of an offer to buy any securities other than the securities described in this prospectus supplement
or an offer to sell or the solicitation of an offer to buy such securities in any circumstances in which such offer or solicitation is
unlawful.
For investors outside the United States: Neither we nor the sales agent
have taken any action that would permit the offering or possession or distribution of this prospectus supplement in any jurisdiction where
action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this
prospectus supplement must inform themselves about, and observe any restrictions relating to, the offering of the securities described
herein and the distribution of this prospectus supplement outside the United States.
Unless otherwise indicated or the context otherwise requires, all references
in this prospectus to “SOPHiA GENETICS,” the “Company,” “we,” “our,” “ours,”
“us” or similar terms refer to SOPHiA GENETICS SA and its consolidated subsidiaries.
Trademarks
We own various trademark registrations and applications, and unregistered
trademarks, including for “SOPHiA GENETICS,” “SOPHiA DDM,” “Alamut,” “SOPHiA Trial Match,”
“SOPHiA Insights,” “SOPHiA
CDx,” “SOPHiA Awareness” and our corporate logo. All
other trade names, trademarks and service marks of other companies appearing in this prospectus supplement are the property of their respective
owners. Solely for convenience, the trademarks and trade names in this prospectus supplement may be referred to without the ® and ™ symbols,
but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under
applicable law, their rights thereto. We do not intend to use or display other companies’ trademarks and trade names to imply a
relationship with, or endorsement or sponsorship of us by, any other companies.
Presentation of Financial Information
Our consolidated financial statements are presented in U.S. dollars
and have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International
Accounting Standards Board (“IASB”). None of the consolidated financial statements were prepared in accordance with generally
accepted accounting principles in the United States (“U.S. GAAP”). The terms “dollar,” “USD” or “$”
refer to U.S. dollars and the terms “Swiss franc” and “CHF” refer to the legal currency of Switzerland, unless
otherwise indicated. We have made rounding adjustments to some of the figures included in this prospectus supplement. Accordingly, any
numerical discrepancies in any table between totals and sums of the amounts listed are due to rounding.
Market and Industry Data
This prospectus supplement contains industry, market and competitive
position data that are based on general and industry publications, surveys and studies conducted by third parties, some of which may not
be publicly available, and our own internal estimates and research. Third-party publications, surveys and studies generally state that
they have obtained information from sources believed to be reliable, but do not guarantee the accuracy and completeness of such information.
While we are not aware of any misstatements regarding the industry, market and competitive position data presented herein, these data
involve a number of assumptions and limitations and contain projections and estimates of the future performance of the industries in which
we operate that are subject to a high degree of uncertainty.
PROSPECTUS SUPPLEMENT SUMMARY
This summary highlights information contained elsewhere in this prospectus
supplement or incorporated by reference in this prospectus supplement. This summary may not contain all the information that may be important
to you, and we urge you to read this entire prospectus supplement and the accompanying prospectus and the documents incorporated by reference
in this prospectus supplement carefully before deciding to invest in our securities.
Our Company
Overview
We are a cloud-native software technology company in the healthcare
space dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. We purposefully
built a cloud-native software platform capable of analyzing data and generating insights from complex multimodal data sets and different
diagnostic modalities. Our platform standardizes, computes and analyzes digital health data and is used across decentralized locations
to break down data silos. This enables healthcare institutions to share knowledge and experiences and to build a collective intelligence.
We envision a future in which all clinical diagnostic test data is channeled through a decentralized analytics platform that will provide
insights powered by large real-world data sets and AI. We believe that a decentralized platform is the most powerful and effective solution
to create the largest network, leverage data and bring the benefits of data-driven medicine to customers and patients globally. In doing
so, we can both support and benefit from growth across the healthcare ecosystem.
Company and Corporate Information
We are a Swiss stock corporation (société anonyme)
incorporated under the laws of Switzerland on March 18, 2011. Our principal executive office is located at Zone artisanale La Pièce
12, 1180 Rolle, Switzerland and our telephone number is +41 21 694 10 60. Our agent for service of process in the United States is SOPHiA
GENETICS, Inc., 185 Dartmouth Street, 5th Floor, Boston, MA 02116, and its telephone number is (617) 982-1210. Our website
is www.sophiagenetics.com. The reference to our website is an inactive textual reference only, and information contained therein
or connected thereto is not incorporated into this prospectus supplement or the registration statement of which the accompanying prospectus
forms a part.
Implications of Being an Emerging Growth
Company and Foreign Private Issuer
We qualify as an “emerging growth company” as defined in
the Jumpstart our Business Startups Act of 2012 (the “JOBS Act”). As an emerging growth company, we may take advantage of
specified reduced reporting and other burdens that are otherwise applicable generally to public companies. These provisions include:
| · | an exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting pursuant
to Section 404 of the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”); and |
| · | to the extent that we no longer qualify as a foreign private issuer, (i) reduced disclosure obligations regarding executive compensation
in our periodic reports and proxy statements and (ii) exemptions from the requirements of holding a non-binding advisory vote on
executive compensation, including golden parachute compensation. |
We may take advantage of these provisions for up to five years or such
earlier time that we are no longer an emerging growth company. We will remain an emerging growth company until the earliest of (i) the
last day of the fiscal year in which we have total annual gross revenues of $1.235 billion or more; (ii) December 31, 2026;
(iii) the date on which we have issued more than $1.0 billion in non-convertible debt during the previous three years; and (iv) the
date on which we are deemed to be a large accelerated filer under the rules of the SEC, which means the market value of our ordinary shares
that are held by
non-affiliates equals or exceeds $700.0 million as of the prior
June 30. We may choose to take advantage of some but not all of these reduced burdens. For example, Section 107 of the JOBS Act also provides
that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards
applicable to public companies. This provision allows an emerging growth company to delay the adoption of certain accounting standards
until those standards would otherwise apply to private companies. This transition period is only applicable under U.S. GAAP. As a result,
we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required or permitted by
the International Accounting Standards Board.
We are also considered a “foreign private issuer.” Accordingly,
we report under the Exchange Act of 1934, as amended (the “Exchange Act”), as a non-U.S. company with foreign private issuer
status. This means that we are exempt from certain provisions of the Exchange Act that are applicable to U.S. domestic public companies,
including:
| · | the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered
under the Exchange Act; |
| · | the sections of the Exchange Act requiring insiders to file public reports of their stock ownership and trading activities and liability
for insiders who profit from trades made in a short period of time; and |
| · | the rules under the Exchange Act requiring the filing with the SEC of quarterly reports on Form 10-Q containing unaudited financial
and other specified information, or current reports on Form 8-K, upon the occurrence of specified significant events. |
We may take advantage of these exemptions until such time as we are
no longer a foreign private issuer. We would cease to be a foreign private issuer at such time as more than 50% of our outstanding voting
securities are held by U.S. residents and any of the following three circumstances applies: (i) the majority of our executive officers
or directors are U.S. citizens or residents, (ii) more than 50% of our assets are located in the United States or (iii) our
business is administered principally in the United States.
In this prospectus supplement and in the documents incorporated by reference
in this prospectus supplement, we have taken advantage of certain of the reduced reporting requirements as a result of being an emerging
growth company and a foreign private issuer. Accordingly, the information contained in this prospectus supplement and in the documents
incorporated by reference in this prospectus supplement may be different than the information you receive from other public companies
in which you hold equity securities.
THE OFFERING
Ordinary Shares Offered by Us |
Ordinary shares having an aggregate offering price of up to $50,000,000. |
|
|
Ordinary Shares Outstanding Before this Offering |
65,032,799 shares. |
|
|
Ordinary Shares Outstanding After this Offering |
78,769,062 shares, after giving effect to the assumed sale by us of $50,000,000 of ordinary shares at an assumed public offering price of $3.64 per share, which was the last reported sale price of our ordinary shares on Nasdaq on August 4, 2023. |
|
|
Plan of Distribution |
“At the market offering” that may be made from time to time through the sales agent. See “Plan of Distribution” on page S-42 of this prospectus supplement. |
|
|
Use of Proceeds |
We intend to use the net proceeds from this offering, if any, for working capital and other general corporate purposes, which may include (i) research and development, in particular to further expand the features, applications and data modalities of our SOPHiA DDM platform and related solutions, applications, products and services, (ii) expanding selling and marketing efforts for our SOPHiA DDM platform and related solutions, applications, products and services, (iii) establishing new and maintaining and growing existing relationships with collaborators and customers across the healthcare system and (iv) obtaining regulatory clearances or approvals for our products and services. We may also use a portion of the net proceeds to in-license or acquire or invest in complementary technologies, products, businesses or assets; however, we have no current plans, commitments or obligations to do so. See “Use of Proceeds.” |
|
|
Risk Factors |
Investing in our ordinary shares involves a high degree of risk. See the “Risk Factors” section beginning on page S-7 of this prospectus supplement and in the documents incorporated by reference in this prospectus supplement and the accompanying prospectus for a discussion of factors you should consider before deciding to invest in our ordinary shares. |
|
|
Nasdaq Symbol |
“SOPH” |
The number of ordinary shares outstanding before and after this offering,
including as discussed under “Dilution”, is based on 65,032,799 ordinary shares outstanding as of June 30, 2023, and excludes:
| · | 612,980 ordinary shares issuable upon the exercise of options outstanding under or accounted for under our Incentive Stock Option
Plan as of June 30, 2023, at a weighted-average exercise price of $3.99 per share; |
| · | 2,515,766 ordinary shares issuable upon the exercise of options outstanding under or accounted for under our 2019 Incentive Stock
Option Plan as of June 30, 2023, at a weighted-average exercise price of $5.98 per share; |
| · | 5,600,982 ordinary shares issuable upon the exercise of options outstanding under or accounted for under our 2021 Equity Incentive
Plan as of June 30, 2023, at a weighted-average exercise price of $8.13 per share; |
| · | 3,387,970 ordinary shares issuable upon vesting of restricted share units outstanding under our 2021 Equity Incentive Plan as of June
30, 2023; |
| · | 9,050,520 additional ordinary shares reserved for future issuance under our 2021 Equity Incentive Plan as of June 30, 2023; and |
| · | 11,865,365 ordinary shares we hold in treasury as of June 30, 2023. |
RISK FACTORS
Investing in our securities involves risk. Before making a decision
to invest in our securities, you should carefully consider the following risks and in our then-most recent Annual Report on Form 20-F,
and any updates to those risk factors in our Reports on Form 6-K incorporated by reference in this prospectus supplement, together with
all of the other information appearing or incorporated by reference in this prospectus supplement and the accompanying prospectus, in
light of your particular investment objectives and financial circumstances. Although we discuss key risks in our discussion of risk factors,
new risks may emerge in the future, which may prove to be significant. We cannot predict future risks or estimate the extent to which
they may affect our business, results of operations, financial condition and prospects.
Risks Related to this Offering
You may experience immediate and substantial dilution in
the book value of your investment.
If you purchase our ordinary shares in this offering, you will experience
immediate dilution in an amount equal to the difference between the purchase price per share and our then-net tangible book value per
ordinary share. See “Dilution.”
The actual number of ordinary shares we will sell under
the sales agreement and the resulting gross proceeds is uncertain.
Subject to certain limitations in the sales agreement and compliance
with applicable law, we have the discretion to deliver a placement notice to the sales agent at any time throughout the term of the sales
agreement. The number of ordinary shares that are sold by the sales agent after we deliver a placement notice will fluctuate based on
the market price of our ordinary shares during the sales period and limits we set in the placement notice. Because the price per share
sold will fluctuate based on the market price of our ordinary shares during the sales period, it is not possible to predict the number
of ordinary shares that will be ultimately sold or the resulting gross proceeds.
The ordinary shares offered in this offering will be sold
in “at the market offerings.” Investors who purchase our ordinary shares in this offering at different times will likely pay
different prices.
Investors who purchase our ordinary shares in this offering at different
times will likely pay different prices, and so may experience different outcomes in their investment results. We will have discretion,
subject to market demand, to vary the timing, prices and numbers of ordinary shares sold, and subject to certain limitations in the sales
agreement, there is no minimum or maximum sales price. Investors may experience a decline in the value of their ordinary shares and dilution
as a result of sales made at prices lower than the prices they paid.
We have broad discretion in the use of the net proceeds
from this offering, and we may not use them effectively.
We currently intend to use the net proceeds from this offering as described
in “Use of Proceeds.” However, our board of directors and our management retain broad discretion in the application of the
net proceeds from this offering and could spend the proceeds in ways that do not improve our results of operations or enhance the value
of our ordinary shares. Our failure to apply these funds effectively could result in financial losses, which could have a material adverse
effect on our business, results of operations, financial condition and prospects.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING
STATEMENTS
This prospectus supplement and the documents incorporated
by reference in this prospectus supplement contain statements that constitute forward-looking statements within the meaning of Section
21E of the Exchange Act and Section 27A of the Securities Act of 1933, as amended (the “Securities Act”). All statements
other than statements of historical facts, including statements regarding our future results of operations and financial position, business
strategy, technology, collaborations and partnerships, as well as plans and objectives of management for future operations are forward-looking
statements. Many of the forward-looking statements contained in this prospectus supplement can be identified by the use of forward-looking
words such as “anticipate,” “believe,” “could,” “expect,” “should,” “plan,”
“intend,” “estimate,” “will” and “potential,” among others.
Forward-looking statements are based on our management’s beliefs
and assumptions and on information available to our management at the time such statements are made. Such statements are subject to risks
and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various
factors, including, but not limited to, those identified under the “Risk Factors” section of this prospectus supplement and
in the documents incorporated by reference in this prospectus supplement. Because forward-looking statements are inherently subject to
risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely
on these forward-looking statements as predictions of future events. Moreover, we operate in an evolving environment. New risk factors
and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except
as required by applicable law, we do not plan to publicly update or revise any forward-looking statements, whether as a result of any
new information, future events, changed circumstances or otherwise. You should read this prospectus supplement, the documents incorporated
by reference in this prospectus supplement and the documents that we have filed as exhibits to the registration statement of which the
accompanying prospectus is a part completely and with the understanding that our actual future results may be materially different from
what we expect.
In addition, statements that “we believe” and similar statements
reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date
of such statements, and while we believe such information forms a reasonable basis for such statements, such information may be limited
or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review
of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to
unduly rely upon these statements.
USE OF PROCEEDS
We may offer and sell our ordinary shares having an aggregate offering
price of up to $50,000,000 from time to time through the sales agent. Because there is no minimum offering amount required as a condition
to close this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this
time.
We intend to use the net proceeds from this offering, if any, for working
capital and other general corporate purposes, which may include (i) research and development, in particular to further expand the features,
applications and data modalities of our SOPHiA DDM platform and related solutions, applications, products and services, (ii) expanding
selling and marketing efforts for our SOPHiA DDM platform and related solutions, applications, products and services, (iii) establishing
new and maintaining and growing existing relationships with collaborators and customers across the healthcare system and (iv) obtaining
regulatory clearances or approvals for our products and services. We may also use a portion of the net proceeds to in-license or acquire
or invest in complementary technologies, products, businesses or assets; however, we have no current plans, commitments or obligations
to do so.
Our expected use of the net proceeds from this offering represents our
current intentions based on our present plans and business condition, which could change as our plans and business conditions evolve.
The amounts and timing of our actual use of the net proceeds from this offering will vary depending on numerous factors. As a result,
we cannot predict with certainty all of the particular uses for any net proceeds to be received or the amounts that we will actually spend
on the uses set forth above. Our board of directors and our management retain broad discretion in the application of the net proceeds
from this offering.
Pending the use of the proceeds from this offering, we intend to invest
the net proceeds in a variety of capital preservation instruments, which may include all or a combination of short-term and long-term
interest-bearing instruments, investment-grade securities, and direct or guaranteed obligations of the U.S. government. We cannot predict
whether the proceeds invested will yield a favorable return.
DIVIDEND POLICY
We have never declared or paid cash dividends on our share capital.
We intend to retain all available funds and any future earnings, if any, to fund the development and expansion of our business, and we
do not anticipate paying any cash dividends in the foreseeable future. Any future determination related to dividend policy will be made
at the discretion of our board of directors and will depend upon, among other factors, our results of operations, financial condition,
capital requirements, contractual restrictions, business prospects and other factors our board of directors may deem relevant.
Under Swiss law, any dividend must be approved by our shareholders.
In addition, our auditors must confirm that the dividend proposal of our board of directors to the shareholders conforms to Swiss statutory
law and our articles of association. A Swiss corporation may pay dividends only if it has sufficient distributable profits from the previous
business year (bénéfice de l’exercice) or brought forward from previous business years (report des bénéfices)
or if it has distributable reserves (réserves à libre disposition), each as evidenced by its audited stand-alone
statutory balance sheet prepared pursuant to Swiss law and after allocations to reserves required by Swiss law and its articles of association
have been deducted. Distributable reserves are generally booked either as free reserves (réserves libres) or as reserves
from capital contributions (apports de capital). Distributions out of share capital, which is the aggregate par value of a corporation’s
issued shares, may be made only by way of a share capital reduction. See “Description of Share Capital and Articles of Association.”
DILUTION
If you purchase our ordinary shares in this offering, you will experience
immediate dilution in an amount equal to the difference between the purchase price per share and our then-net tangible book value per
ordinary share.
Net tangible book value per share is determined by dividing our tangible
net worth (defined as total assets, less intangible assets, less total liabilities) by the number of our ordinary shares outstanding.
Our historical net tangible book value as of June 30, 2023 was $148.9 million, or $2.29 per share. After giving effect to the assumed
sale by us of $50,000,000 of ordinary shares at an assumed public offering price of $3.64 per share, which was the last reported sale
price of our ordinary shares on Nasdaq on August 4, 2023, and after deducting estimated commissions and estimated offering expenses payable
by us, our as adjusted net tangible book value as of June 30, 2023 would have been $197.1 million, or $2.50 per ordinary share, representing
an immediate increase in the as adjusted net tangible book value of $0.21 per ordinary share attributable to the purchasers in this offering
and immediate dilution of $1.14 per ordinary share to purchasers in this offering.
DESCRIPTION OF SHARE CAPITAL AND ARTICLES OF
ASSOCIATION
Share Capital
As of June 30, 2023, our share capital as registered with the commercial
register of the Canton of Vaud, Switzerland (the “Commercial Register”) amounted to CHF 3,844,908.20 and was divided into
76,898,164 ordinary shares, with a par value of CHF 0.05 per share.
Changes in Our Share Capital During the Last Three Fiscal Years
In this section, share amounts are presented as of the date of the relevant
transaction. Since January 1, 2020, our share capital has changed as follows:
| · | On May 29, 2020, our share capital as registered with the Commercial Register was updated to reflect the issuance of 39,975 ordinary
shares out of conditional share capital; |
| · | On June 25, 2020, our share capital as registered with the Commercial Register on June 25, 2020, was increased by issuing 283,224
Series F preferred shares; |
| · | On September 23, 2020, our share capital as registered with the Commercial Register on September 29, 2020 was increased by issuing
182,623 Series F preferred shares; |
| · | On June 25, 2021, our share capital as registered with the Commercial Register was updated to reflect the issuance of 74,265 ordinary
shares out of conditional share capital; |
| · | In the one-to-twenty share split of all issued shares effected on June 30, 2021, each of our issued shares was split into 20 shares
of the same class with a par value of CHF 0.05 per share; |
| · | On July 26, 2021, our entire share capital as registered with the Commercial Register on July 27, 2021 was converted into ordinary
shares; |
| · | On July 26, 2021, our share capital as registered with the Commercial Register on July 27, 2021 was increased by issuing 14,111,111
ordinary shares; |
| · | On August 24, 2021, our share capital as registered with the Commercial Register on August 25, 2021 was increased by issuing 519,493
ordinary shares; |
| · | On April 26, 2022, our share capital as registered with the Commercial Register on April 29, 2022 was updated to reflect the issuance
of 2,540,560 ordinary shares out of conditional share capital; and |
| · | On June 26, 2023, our share capital as registered with the Commercial Register on June 29, 2023 was increased by issuing 10,500,000
ordinary shares. |
Articles of Association
Ordinary Capital Increase, Capital Range and Conditional Share
Capital
Under Swiss law, we may increase our share capital (capital-actions)
with a resolution of the general meeting of shareholders (ordinary capital increase) that must be carried out by the board of directors
within six months of the respective general meeting in order to become effective. Under our articles of association and Swiss law, in
the case of subscription and increase against payment of contributions in cash, a resolution passed by a majority of the shares represented
at the general meeting of shareholders is required. In the case of subscription and increase against contributions in kind or to fund
acquisitions in kind, when shareholders’ statutory pre-emptive subscription rights or advance subscription rights are limited or
withdrawn or where transformation of freely disposable equity into share capital is involved, a
resolution passed by two-thirds of the shares represented at a general
meeting of shareholders and the majority of the par value of the shares represented is required.
Furthermore, under the Swiss Code of Obligations (Code des obligations)
(the “Code of Obligations”), our shareholders, by a resolution passed by two-thirds of the shares represented at a general
meeting of shareholders and the majority of the par value of the shares represented, can:
| · | adopt conditional share capital (capital-actions conditionnel) in the aggregate amount of up to 50% of the share capital for
the purpose of issuing shares in connection with, among other things, option and conversion rights granted to shareholders, the creditors
of bonds and similar debt instruments, employees, members of the board of directors of the Company or of any group company, or to any
third parties; and |
| · | may, in the form of capital range (marge de fluctuation du capital), authorize our board of directors to increase and/or decrease
our share capital by up to 50% of the share capital, by issuing or canceling shares, or by increasing or decreasing the par value of shares,
including through the creation of conditional share capital; such capital range is to be utilized by the board of directors within a period
determined by the shareholders but not exceeding five years from the date of the shareholder approval. |
Pre-Emptive and Advance Subscription Rights
Pursuant to the Code of Obligations, shareholders have pre-emptive subscription
rights (droits de souscription préférentiels) to subscribe for new issuances of shares. With respect to conditional
capital, shareholders have (i) pre-emptive subscription rights for the subscription of option rights and (ii) advance subscription rights
(droit de souscription préalable) for the subscription of bonds and similar debt instruments to which option or conversion
rights are attached.
A resolution passed at a general meeting of shareholders by two-thirds
of the shares represented and the majority of the par value of the shares represented may authorize our board of directors to withdraw
or limit pre-emptive subscription rights or advance subscription rights in certain circumstances.
If pre-emptive subscription rights are granted, but not exercised, the
board of directors may allocate the unexercised pre-emptive subscription rights at its discretion.
Our Capital Range
Under our articles of association, our board of directors is authorized
at any time, including to prevent takeovers and changes in control, until June 26, 2028 at the latest to increase or decrease our nominal
share capital by a maximum aggregate amount of CHF 4,979,862.30 (upper limit) or CHF 3,319,908.20 (lower limit) through the issuance of
not more than 33,199,082 shares, which would have to be fully paid-in, or cancellation of not more than 33,199,082 shares, each with a
par value of CHF 0.05 per share, as applicable, or by increasing or reducing the par value of the existing shares within the limits of
the capital range or by simultaneous reduction and re-increase of the share capital.
Increases and decreases in partial amounts are permitted. The board
of directors has the power to determine the type of contributions, the issue price and the date on which the dividend entitlement starts.
With respect to our capital range, the board of directors is authorized
by our articles of association to withdraw or to limit the pre-emptive subscription rights of shareholders, and to allocate them to third
parties or to us, in the event that the newly issued shares are issued under the following circumstances:
| · | if the issue price of the new registered shares is determined by reference to the market price; |
| · | for raising of equity capital (including private placements) in a fast and flexible manner, which would not be possible, or might
only be possible with great difficulty or delays or at significantly |
less favorable conditions, without the exclusion of the statutory
pre-emptive subscription rights of the existing shareholders;
| · | for the acquisition of companies, parts of companies or participations, for the acquisition of products, intellectual property or
licenses by or for investment projects of the Company or any of its group companies, or for the financing or refinancing of any of such
transactions through a placement of shares; |
| · | for purposes of broadening the shareholder constituency of the Company in certain geographic, financial or investor markets, for purposes
of the participation of strategic partners including financial investors, or in connection with the listing of new shares on domestic
or foreign stock exchanges; |
| · | for purposes of granting an over-allotment option or an option to purchase additional shares in a placement or sale of shares to the
respective initial purchaser(s) or underwriter(s); |
| · | for the participation of members of the board of directors, members of the executive committee, employees, contractors, consultants
or other persons performing services for the benefit of the Company or any of its group companies; |
| · | following a shareholder or a group of shareholders acting in concert having accumulated shareholdings in excess of 15% of our share
capital registered in the Commercial Register without having submitted to all other shareholders a takeover offer recommended by the board
of directors; |
| · | for the defense of an actual, threatened or potential takeover bid, that the board of directors, upon consultation with an independent
financial adviser retained by it, has not recommended to the shareholders for acceptance on the basis that the board of directors has
not found the takeover bid to be financially fair to the shareholders or not to be in the Company’s interest; or |
| · | for other valid grounds in the sense of Article 652b para. 2 of the Code of Obligations. |
This authorization is exclusively linked to the particular available
capital range set out in the respective article. If the period to increase our share capital out of the capital range lapses without having
been used by the board of directors, the authorization to withdraw or to limit the pre-emptive subscription rights lapses simultaneously
with such capital.
Our Conditional Share Capital
Conditional Share Capital for Financing, Acquisitions and Other Purposes
Our nominal share capital may be increased, including to prevent takeovers
and changes in control, by a maximum aggregate amount of CHF 1,079,954.10 through the issuance of not more than 21,599,082 ordinary
shares, which would have to be fully paid-in, each with a par value of CHF 0.05 per share, by the exercise of option and conversion rights
granted in connection with warrants, convertible bonds or similar instruments of the Company or one of our subsidiaries. Shareholders
will not have pre-emptive subscription rights in such circumstances, but will have advance subscription rights to subscribe for such warrants,
convertible bonds or similar instruments. The holders of warrants, convertible bonds or similar instruments are entitled to the new shares
upon the occurrence of the applicable conversion feature.
When issuing convertible bonds, warrants or similar instruments, the
board of directors is authorized to withdraw or to limit the advance subscription right of shareholders:
| · | for the purpose of financing or refinancing, or the payment for, the acquisition of companies, parts of companies, participations,
intellectual property rights, licenses or investments; |
| · | if the issuance occurs in domestic or international capital markets, including private placements; |
| · | following a shareholder or a group of shareholders acting in concert having accumulated shareholdings in excess of 15% of the share
capital registered in the Commercial Register without having submitted to all other shareholders a takeover offer recommended by the board
of directors; |
| · | for the defense of an actual, threatened or potential takeover bid that the board of directors, upon consultation with an independent
financial adviser retained by it, has not recommended to the shareholders to accept on the basis that the board of directors has not found
the takeover bid to be financially fair to the shareholders or not to be in the Company’s interest; or |
| · | if the financial instruments are issued on appropriate terms. |
To the extent that the advance subscription rights are withdrawn or
limited, (i) the convertible bonds, warrants or similar instruments are to be issued at market conditions; (ii) the term to
exercise the convertible bonds, warrants or similar instruments may not exceed ten years from the date of issue of the respective instrument
and (iii) the conversion, exchange or exercise price of the convertible bonds, warrants or similar instruments has to be set with
reference to or be subject to change based upon the valuation of the Company’s equity or market conditions.
Conditional Share Capital for Employee Participation
Our nominal share capital may, to the exclusion of the pre-emptive subscription
rights and advance subscription rights of shareholders, be increased by a maximum aggregate amount of CHF 740,000 through the (direct
or indirect) issuance of not more than 14,800,000 ordinary shares, which would have to be fully paid-in, each with a par value of CHF
0.05 per share, through the exercise or mandatory exercise of rights to acquire shares or through obligations to acquire shares that were
granted to or imposed on members of the board of directors, employees, contractors or consultants of the Company or of one of our subsidiaries
or other persons providing services to the Company or to a subsidiary through one or more equity incentive plans created by the board
of directors.
Uncertificated Securities
Our shares are in the form of uncertificated securities (droits-valeurs,
within the meaning of Article 973c of the Code of Obligations). In accordance with Article 973c of the Code of Obligations, we maintain
a non-public register of uncertificated securities (registre des droits-valeurs). We may at any time convert uncertificated securities
into share certificates (including global certificates), one kind of certificate into another, or share certificates (including global
certificates) into uncertificated securities. Following entry in the share register, a shareholder may at any time request from us
a written confirmation in respect of his or her shares. Shareholders are not entitled, however, to request the conversion and/or printing
and delivery of share certificates. We may print and deliver certificates for shares at any time.
General Meeting of Shareholders
Ordinary/Extraordinary Meetings, Powers
The general meeting of shareholders is our supreme corporate body. Under
Swiss law, an annual general meeting of shareholders must be held annually within six months after the end of a corporation’s financial
year. In our case, this generally means on or before June 30. In addition, extraordinary general meetings of shareholders may be held.
A general meeting of shareholders may take place at different places
simultaneously if the votes of the participants are immediately transmitted to all meeting venues (multilocal shareholders’ meeting).
If the articles of association so permit, a general meeting of shareholders may be held outside Switzerland. The board of directors may
allow shareholders that are not present at the meeting venue of the general meeting of shareholders to participate and exercise their
rights electronically (“hybrid shareholder meeting”). A general meeting of shareholders without a physical meeting venue but
that takes place using electronic means (“virtual shareholder meeting”) may be held, subject to certain legal requirements
and if
the articles of association so allow. Our articles of association provide
for general meetings of shareholders outside Switzerland and virtual shareholder meetings.
The following powers are vested exclusively in the general meeting of
shareholders:
| · | adopting and amending the articles of association, including the change of a company’s purpose or domicile; |
| · | electing the members of the board of directors, the chairman of the board of directors, the members of the compensation committee,
the auditors and the independent proxy; |
| · | approving the management report, the annual statutory and consolidated financial statements and deciding on the allocation of profits
as shown on the balance sheet, in particular with regard to dividends; |
| · | approving the aggregate amount of compensation of members of the board of directors and the executive committee; |
| · | determining the interim dividends and the approval of the interim financial statements required for this purpose; |
| · | resolving on the repayment of the statutory capital reserve (réserve légale); |
| · | discharging the members of the board of directors and the executive committee from liability with respect to their conduct of business; |
| · | the delisting of the Company's equity securities; |
| · | the approval of the report on non-financial matters pursuant to article 964c the Code of Obligations (if applicable); |
| · | dissolving a company with or without liquidation; and |
| · | deciding matters reserved to the general meeting of shareholders by law or the articles of association or submitted to it by the board
of directors. |
An extraordinary general meeting of shareholders may be called by a
resolution of the board of directors or the general meeting of shareholders or, under certain circumstances, by the company’s
auditors, liquidator or the representatives of bondholders, if any. In addition, the board of directors is required to convene an
extraordinary general meeting of shareholders if shareholders representing at least 5% of our share capital or of the voting rights
request such general meeting of shareholders in writing. A request for an extraordinary general meeting of shareholders must set
forth the items to be discussed and the proposals to be acted upon. Further, the board of directors must convene an extraordinary
general meeting of shareholders and propose financial restructuring measures if, based on our stand-alone annual statutory balance
sheet, half of our share capital and statutory reserves are not covered by our assets and a contemplated restructuring measure falls
within the competence of the general meeting of shareholders.
Voting and Quorum Requirements
Shareholder resolutions and elections (including elections of members
of the board of directors) require the affirmative vote of the majority of shares represented at the general meeting of shareholders,
unless otherwise stipulated by law or our articles of association.
Under Swiss law and our articles of association, a resolution of the
general meeting of shareholders passed by two-thirds of the votes and the majority of the par value of the shares, each as represented
at the meeting, is required for:
| · | amending the Company’s corporate purpose; |
| · | creating shares with privileged voting rights; |
| · | cancelling or amending the transfer restrictions of shares; |
| · | introducing a capital range or conditional share capital; |
| · | increasing share capital out of equity, against contributions in-kind or by set-off against a claim or by granting specific benefits; |
| · | limiting or withdrawing shareholders’ pre-emptive subscription rights; |
| · | changing the currency of the share capital; |
| · | introducing a casting vote for the person chairing the general meeting of shareholders; |
| · | changing a company’s domicile; |
| · | delisting the Company's equity securities; |
| · | introducing an arbitration clause in the articles of association; |
| · | amending or repealing the voting and recording restrictions, the provision setting a maximum board size or the indemnification provision
for the board of directors and the executive committee set forth in our articles of association; |
| · | converting registered shares into bearer shares; |
| · | the combination of shares; |
| · | removing the chairman or any member of the board of directors before the end of his or her term of office; and |
| · | dissolving or liquidating the Company. |
The same voting requirements apply to resolutions regarding transactions
among corporations based on Switzerland’s Federal Act on Mergers, Demergers, Transformations and the Transfer of Assets of 2003,
as amended (the “Swiss Merger Act”). See “—Articles of Association—Compulsory Acquisitions; Appraisal Rights.”
In accordance with Swiss law and generally accepted business practices,
our articles of association do not provide quorum requirements generally applicable to general meetings of shareholders. To this extent,
our practice varies from Nasdaq listing standards, which require an issuer to provide in its bylaws for a generally applicable quorum
and that such quorum may not be less than one-third of the outstanding voting shares.
Notice
General meetings of shareholders must be convened by the board of directors
at least 20 days before the date of the meeting. The general meeting of shareholders is convened by way of a notice appearing in our official
publication medium, currently the Swiss Official Gazette of Commerce. Registered shareholders may also be informed in a form that allows
proof by text. The notice of a general meeting of shareholders must state the date, the starting time, the form and location of the meeting,
the items on the agenda, the motions to the shareholders including a short explanation for these motions, the name and address of the
independent representative and, in case of elections, the names of the nominated candidates. A resolution on a matter which is not on
the agenda may not be passed at a general meeting
of shareholders, except for motions to convene an extraordinary general
meeting of shareholders or to initiate a special investigation, on which the general meeting of shareholders may vote at any time. No
previous notification is required for motions concerning items included in the agenda or for debates that do not result in a vote.
All owners or representatives of our shares may, if no objection is
raised, hold a general meeting of shareholders without complying with the formal requirements for convening general meetings of shareholders
(a universal meeting). This universal meeting of shareholders may discuss and pass binding resolutions on all matters within the
purview of the general meeting of shareholders, provided that the owners or representatives of all the shares are present at the meeting.
Agenda Requests
Pursuant to Swiss law and our articles of association, one or more shareholders
whose combined shareholdings represent at least 0.5% of the share capital or of the voting rights may request that an item, or a proposal
with respect to an existing agenda item, be included in the agenda for a general meeting of shareholders.
To be timely, the shareholder’s request must be received by us
generally at least 45 calendar days in advance of the meeting. The request must be made in writing and contain, for each of the agenda
items, the following information:
| · | a brief description of the business desired to be brought before the general meeting of shareholders and the reasons for conducting
such business at the general meeting of shareholders; |
| · | the motions regarding the agenda item; |
| · | the name and address, as they appear in the share register, of the shareholder proposing such business; |
| · | the number of shares which are beneficially owned by such shareholder (including documentary support of such beneficial ownership); |
| · | the dates upon which the shareholder acquired such shares; |
| · | any material interest of the proposing shareholder in the proposed business; |
| · | a statement in support of the matter; and |
| · | all other information required under the applicable laws and stock exchange rules. |
In addition, if the shareholder intends to solicit proxies from the
shareholders of a company, such shareholder shall notify the company of this intent in accordance with SEC Rule 14a-4 and/or Rule 14a-8.
Our business report, the compensation report and the auditor’s
report must be made available to the shareholders no later than 20 days prior to the general meeting of shareholders.
Voting Rights
Each of our ordinary shares entitles a holder to one vote. The ordinary
shares are not divisible. The right to vote and the other rights of share ownership may only be exercised by shareholders (including any
nominees) or usufructuaries who are entered in the share register at a cut-off date determined by the board of directors. Those entitled
to vote in the general meeting of shareholders may be represented by the independent proxy holder (annually elected by the general meeting
of shareholders), by its legal representative or by another proxy, who need not be a shareholder, with written authorization to act as
proxy. The chairman has the power to decide whether to recognize a power of attorney.
Our articles of association contain provisions that prevent investors
from acquiring and exercising voting rights exceeding 15% of our issued share capital. Specifically, if an individual or legal entity
acquires ordinary shares and, as a result, directly or indirectly, has voting rights with respect to more than 15% of the registered share
capital recorded in the Commercial Register, the registered shares exceeding the limit of 15% shall be entered in the share register as
shares without voting rights (limitation à l’inscription). This restriction applies equally to parties acting in concert
and to shares held or acquired via a nominee, including via Cede & Co., New York (or any successor), as the nominee of The Depository
Trust Company (“DTC”), New York, acting in its capacity as clearing nominee. Specifically, if shares are being held by a nominee
for third-party beneficiaries, which control (alone or together with third parties) voting rights with respect to more than 15% of the
share capital recorded in the Commercial Register, our articles of association provide that the board of directors may cancel the registration
of the shares with voting rights held by such nominee in excess of the limit of 15%. Furthermore, our articles of association contain
provisions that allow the board of directors to make the registration with voting rights of shares held by a nominee subject to conditions,
limitations and reporting requirements or to impose or adjust such conditions, limitations and requirements once registered. Our articles
of association also contain provisions that prevent shareholders and proxies from exercising voting rights attached to their own or represented
ordinary shares that would collectively exceed 15% the share capital recorded in the commercial register. This restriction applies equally
to parties acting in concert and to shares held or acquired via a nominee, as described above, but not to the independent proxy acting
as proxy on behalf of shareholders.
However, any shareholders who held more than 15% prior to our initial
public offering remain registered with voting rights for such shares. Furthermore, the board of directors may in special cases approve
exceptions to these restrictions.
Dividends and Other Distributions
Our board of directors may propose to shareholders that a dividend or
interim dividend or other distribution be paid but cannot itself authorize the distribution. Dividend and interim dividend payments require
a resolution passed by a majority of the shares represented at a general meeting of shareholders. In addition, our auditors must confirm
that the dividend proposal of our board of directors conforms to Swiss statutory law and our articles of association.
Under Swiss law, we may pay dividends only if we have sufficient distributable
profits from the previous business year (bénéfice de l’exercice) or brought forward from the previous business
years (report des bénéfices) or if we have distributable capital reserves (réserve légale issue
du capital), each as evidenced by audited stand-alone statutory annual or interim financial statements prepared pursuant to Swiss
law, and after allocations to reserves required by Swiss law and by the articles of association have been deducted.
Under the Code of Obligations, at least 5% of our annual profit must
be retained as statutory profit reserve (réserve légale). If there is a loss carried forward, such loss must be eliminated
before allocation to the statutory profit reserve. The statutory profit reserve shall be accumulated until it reaches, together with the
statutory capital reserve, 50% of our share capital recorded in the Commercial Register. In addition, we have to allocate, among other
things, the net proceeds of share issuances to the statutory capital reserve. The Code of Obligations permits us to accrue additional
reserves. Further, a purchase of our own shares (whether by us or a subsidiary) reduces the distributable reserves in an amount corresponding
to the purchase price of such own shares. Finally, the Code of Obligations under certain circumstances requires the creation of revaluation
reserves which are not distributable.
Distributions out of issued share capital (i.e., the aggregate par value
of our issued shares) are not allowed and may be made only by way of an ordinary capital reduction or within a capital range that
(also) allows for a capital reduction (see “—Articles of Association—Ordinary Capital Increase, Capital Range and Conditional
Share Capital”). An ordinary capital reduction requires a resolution passed by a majority of the shares represented at a general
meeting of shareholders. The board of directors must publish a call to creditors in the Swiss Official Gazette of Commerce in which creditors
are advised that they may request, subject to certain conditions, security for their claims within 30 days of the publication of
the
creditor call. A licensed audit expert must then confirm, based on the
results of the call to creditors, that the claims of the creditors remain fully covered despite the reduction in our share capital
recorded in the Commercial Register. If all requirements for an ordinary capital reduction have been met, the board of directors has to
amend the articles of association in a public deed. Our share capital may be reduced below CHF 100,000 only if and to the extent
that at the same time the statutory minimum share capital of CHF 100,000 is reestablished by sufficient new fully paid-up capital.
An ordinary capital reduction must be completed within six months after the resolution of the general meeting of shareholders.
Our board of directors determines the date on which the dividend entitlement
starts. Dividends are usually due and payable shortly after the shareholders have passed the resolution approving the payment, but shareholders
may also resolve at the annual general meeting of shareholders to pay dividends in quarterly or other installments.
Transfer of Shares
Shares in uncertificated form (droits-valeurs) may only be transferred
by way of assignment. Shares or the beneficial interest in shares, as applicable, credited in a securities account may only be transferred
when a credit of the relevant intermediated securities to the acquirer’s securities account is made in accordance with applicable
rules. Our articles of association provide that in the case of securities held with an intermediary such as a registrar, transfer agent,
trust corporation, bank or similar entity, any transfer, grant of a security interest or usufructuary right in such intermediated securities
and the appurtenant rights associated therewith requires the cooperation of the intermediary in order for such transfer, grant of a security
interest or usufructuary right to be valid against us.
Voting rights may be exercised only after a shareholder has been entered
in the share register (registre des actions) with his or her name and address (in the case of legal entities, the registered office)
as a shareholder with voting rights. For a discussion of the restrictions applicable to the control and exercise of voting rights, see
“—Articles of Association—Voting Rights.”
Inspection of Books and Records
Under the Code of Obligations, a shareholder has a right to inspect
the share register with respect to his or her own shares and otherwise to the extent necessary to exercise his or her shareholder rights.
No other person has a right to inspect the share register. Shareholders holding in the aggregate at least 5% of our nominal share capital
or of our voting rights have the right to inspect our books and correspondence, subject to the safeguarding of our business secrets and
other legitimate interests. Our board of directors is required to decide on an inspection request within four months after receipt of
such request. Denial of the request will need to be justified in writing. If an inspection request is denied by the board of directors,
shareholders may request the order of an inspection by the court within thirty days. See “—Comparison of Swiss Law and Delaware
Law—Inspection of books and records.”
Special Investigation
If a shareholder has exercised its information or inspection rights,
such shareholder may propose to the general meeting of shareholders that specific facts be examined by a special examiner in
a special investigation. If the general meeting of shareholders approves the proposal, we or any shareholder may, within 30 calendar
days after the general meeting of shareholders, request a court at our registered office (currently Rolle, Canton of Vaud, Switzerland)
to appoint a special examiner. If the general meeting of shareholders rejects the request, one or more shareholders representing
at least 5% of our share capital or voting rights may request that the court appoint a special examiner. The court will issue such
an order if the petitioners can demonstrate that members of the board of directors or our executive committee infringed the law or
our articles of association and that such violation is suitable to cause a damage to the Company or the shareholders. The costs of the
investigation would generally be allocated to us and only in exceptional cases to the petitioners.
Compulsory Acquisitions; Appraisal Rights
Business combinations and other transactions that are governed by the
Swiss Merger Act (i.e., mergers, demergers, transformations and certain asset transfers) are binding on all shareholders. A statutory
merger or demerger requires approval of two-thirds of the shares represented at a general meeting of shareholders and the majority of
the par value of the shares represented.
If a transaction under the Swiss Merger Act receives all of the necessary
consents, all shareholders are compelled to participate in such transaction.
Swiss corporations may be acquired by an acquirer through the direct
acquisition of the shares of the Swiss corporation. The Swiss Merger Act provides for the possibility of a so-called “cash-out”
or “squeeze-out” merger with the approval of holders of 90% of the issued shares. In these limited circumstances, minority
shareholders of the corporation being acquired may be compensated in a form other than through shares of the acquiring corporation (for
instance, through cash or securities of a parent corporation of the acquiring corporation or of another corporation). For business combinations
effected in the form of a statutory merger or demerger and subject to Swiss law, the Swiss Merger Act provides that if equity rights have
not been adequately preserved or compensation payments in the transaction are unreasonable, a shareholder may request the competent court
to determine a reasonable amount of compensation.
In addition, under Swiss law, the sale of “all or substantially
all of our assets” by us may require the approval of two-thirds of the number of shares represented at a general meeting of shareholders
and the majority of the par value of the shares represented. Whether a shareholder resolution is required depends on the particular transaction,
including whether the following test is satisfied:
| · | a core part of our business is sold, without which it is economically impracticable or unreasonable to continue to operate the remaining
business; |
| · | our assets, after the divestment, are not invested in accordance with our corporate purpose as set forth in the articles of association;
and |
| · | the proceeds of the divestment are not earmarked for reinvestment in accordance with our corporate purpose but, instead, are intended
for distribution to our shareholders or for financial investments unrelated to our corporate purpose. |
A shareholder of a Swiss corporation participating in certain major
corporate transactions may, under certain circumstances, be entitled to appraisal rights. As a result, such shareholder may, in addition
to the consideration (be it in shares or in cash) receive an additional amount to ensure that the shareholder receives the fair value
of the shares held by the shareholder. Following a statutory merger or demerger, pursuant to the Swiss Merger Act, shareholders can file
an appraisal action against the surviving company. If the consideration is deemed inadequate, the court will determine an adequate compensation
payment.
Board of Directors
Our articles of association provide that the board of directors shall
consist of at least three and not more than eight members.
The members of the board of directors and the chairman are elected annually
by the general meeting of shareholders for a period until the completion of the subsequent annual general meeting of shareholders and
are eligible for re-election. Each member of the board of directors must be elected individually.
Powers
The board of directors has the following non-delegable and inalienable
powers and duties:
| · | the ultimate direction of the business of the Company and issuing of the relevant directives; |
| · | laying down the organization of the Company; |
| · | formulating accounting procedures, financial controls and financial planning; |
| · | nominating and removing persons entrusted with the management and representation of the Company and regulating the power to sign for
the Company; |
| · | the ultimate supervision of those persons entrusted with management of the Company, with particular regard to adherence to law, our
articles of association and regulations and directives of the Company; |
| · | issuing the business report, the compensation report and, if applicable, the report on non-financial matters and any other reports
as required by law, and preparing for the general meeting of shareholders and carrying out its resolutions; and |
| · | submission of an application for debt-restructuring moratorium and the notification of the court in case of over-indebtedness. |
The board of directors may, while retaining such non-delegable and inalienable
powers and duties, delegate some of its powers, in particular direct management, to a single or to several of its members, committees
or to third parties (such as executive officers) who need be neither members of the board of directors nor shareholders. Pursuant to Swiss
law and our articles of association, details of the delegation and other procedural rules such as quorum requirements have been set in
the organizational rules established by the board of directors.
Indemnification of Executive Officers and Directors
Subject to Swiss law, our articles of association provide for indemnification
of the existing and former members of the board of directors and the executive committee and their heirs, executors and administrators
against liabilities arising in connection with the performance of their duties in such capacity, and permit us to advance the expenses
of defending any act, suit or proceeding to our directors and executive officers to the extent not included in insurance coverage or advanced
by third parties.
In addition, under general principles of Swiss employment law, an employer
may be required to indemnify an employee against losses and expenses incurred by such employee in the proper execution of his or her duties
under the employment agreement with the employer. See “—Comparison of Swiss Law and Delaware Law—Indemnification of
directors and executive officers and limitation of liability.”
Conflicts of Interest, Management Transactions
The members of the board of directors and the executive committee are
required to immediately and fully inform the board of directors about conflicts of interests concerning them. The board of directors is
furthermore required to take measures in order to protect the interests of the company. More generally, the Code of Obligations requires
our directors and executive officers to safeguard the Company’s interests and imposes a duty of loyalty and duty of care on our
directors and executive officers. This rule is generally understood to disqualify directors and executive officers from participation
in decisions that directly affect them. Our directors and executive officers are personally liable to us for breaches of these obligations.
In addition, Swiss law contains provisions under which directors and all persons engaged in the Company’s management are liable
to the Company, each shareholder and the Company’s creditors for damages caused by an intentional or negligent violation of their
duties. Furthermore, Swiss law contains a provision under which payments made to any of the Company’s shareholders or directors
or any person related to any such shareholder or director, other than payments made at arm’s length, must be repaid to the Company
if such shareholder or director acted in bad faith.
Our board of directors has adopted a Code of Ethics and other policies
that cover a broad range of matters, including the handling of conflicts of interest.
Principles of the Compensation of the Board of Directors and
the Executive Committee
Pursuant to Swiss law, the aggregate amount of compensation of the board
of directors and the persons whom the board of directors has, fully or partially, entrusted with the management (which we refer to as
our “executive committee”) of the Company has to be submitted to our shareholders for approval each year. All of our executive
officers named in “Management” of our then-most recent Annual Report on Form 20-F are deemed to be members of our executive
committee.
The board of directors must issue, on an annual basis, a written compensation
report that must be reviewed by our auditors. The compensation report must disclose, among other things, all compensation granted by the
Company, directly or indirectly, to current members of the board of directors and the executive committee and, to the extent related to
their former role within the Company or not on customary market terms, to former members of the board of directors and former executive
officers. If variable compensation is approved prospectively, the board of directors must submit the compensation report to the general
meeting of shareholders for a consultative vote.
The disclosure concerning compensation, loans and other forms of indebtedness
must include the aggregate amount for the board of directors and the executive committee, respectively, as well as the particular amount
for each member of the board of directors and for the highest-paid executive officer, specifying the name and function of each of these
persons.
We are prohibited from granting certain forms of compensation to members
of our board of directors and executive committee, such as:
| · | severance payments that are contractually agreed or provided for in the articles of association; remuneration that is due until the
termination of the contracts does not constitute a severance payment; |
| · | compensation related to a ban on competition that exceeds the average remuneration for the last three financial years, or compensation
related to a ban on competition that is not justified on business grounds; |
| · | remuneration paid on conditions other than the customary market conditions connected with a previous activity as a corporate body
of the company: |
| · | joining bonuses that do not compensate for a verifiable financial disadvantage; |
| · | commission paid for taking over or transferring undertakings or parts thereof; |
| · | loans, credit facilities, other forms of indebtedness, pension benefits not based on occupational pension schemes and performance-based
compensation not provided for in the articles of association; and |
| · | the allocation of equity securities or conversion and option rights not provided for in the articles of association. |
Compensation to members of the board of directors and the executive
committee for activities in entities that are directly or indirectly controlled by the Company is prohibited if (i) the compensation
would be prohibited if it were paid directly by the Company, (ii) the articles of association do not provide for it, or (iii) the
compensation has not been approved by the general meeting of shareholders.
Each year, the general meeting of shareholders has to vote on the proposals
of the board of directors with respect to:
| · | the maximum aggregate amount of compensation of the board of directors for the term of office until the next annual general meeting
of shareholders; |
| · | the maximum aggregate amount of fixed compensation of the executive committee for the following financial year; and |
| · | the maximum aggregate amount of variable compensation of the executive committee for the current financial year. |
The board of directors may submit for approval at the general meeting
of shareholders deviating or additional proposals relating to the same or different periods.
If, at the general meeting of shareholders, the shareholders do not
approve a compensation proposal of the board of directors, the board of directors must prepare a new proposal, taking into account all
relevant factors, and submit the new proposal for approval by the same general meeting of shareholders at a subsequent extraordinary general
meeting of shareholders or the next annual general meeting of shareholders.
In addition to fixed compensation, members of the board of directors
and the executive committee may be paid variable compensation depending on the achievement of certain performance criteria. The performance
criteria may include individual targets, targets of the Company or parts thereof and targets in relation to the market, other companies
or comparable benchmarks, taking into account the position and level of responsibility of the recipient of the variable compensation.
The board of directors or, where delegated to it, the compensation committee shall determine the relative weight of the performance criteria
and the respective target values.
Compensation may be paid or granted in the form of cash, shares, financial
instruments, in kind, or in the form of other types of benefits. The board of directors or, where delegated to it, the compensation committee
shall determine grant, vesting, exercise and forfeiture conditions.
Borrowing Powers
Neither Swiss law nor our articles of association restrict our power
to borrow and raise funds. The decision to borrow funds is made by or under the direction of our board of directors and no approval by
the shareholders is required in relation to any such borrowing.
Repurchases of Shares and Purchases of Own Shares
The Code of Obligations limits our ability to repurchase and hold our
own shares. We and our subsidiaries may repurchase shares only to the extent that (i) we have freely distributable reserves in the
amount of the purchase price and (ii) the aggregate par value of all shares held by us does not exceed 10% of our share capital.
Pursuant to Swiss law, where shares are acquired in connection with a transfer restriction set out in the articles of association, the
foregoing upper limit is 20%. If we own shares that exceed the threshold of 10% of our share capital, the excess must be sold or cancelled
by means of a capital reduction within two years.
Shares held by us or our subsidiaries are not entitled to vote at the
general meeting of shareholders but are entitled to the economic benefits applicable to the shares generally, including dividends and
pre-emptive subscription rights in the case of share capital increases.
In addition, selective share repurchases are only permitted under certain
circumstances. Within these limitations, as is customary for Swiss corporations, we may, subject to applicable law, purchase and sell
our own shares from time to time in order to meet imbalances of supply and demand, to provide liquidity and to even-out variances in the
market price of shares.
Notification and Disclosure of Substantial Share Interests
The disclosure obligations generally applicable to shareholders of Swiss
corporations under the Federal Act on Financial Market Infrastructures and Market Conduct in Securities and Derivatives Trading, or the
Financial Market Infrastructure Act (the “FMIA”), do not apply to us since our shares are not listed on a Swiss exchange.
Mandatory Bid Rules
The obligation of any person or group of persons that acquires more
than one third of a company’s voting rights to submit a cash offer for all the outstanding listed equity securities of the relevant
company at a minimum price pursuant to the FMIA does not apply to us since our shares are not listed on a Swiss exchange.
Stock Exchange Listing
Our ordinary shares are listed on Nasdaq under the symbol “SOPH.”
Transfer Agent and Registrar of Shares
Our share register is kept by Computershare Trust Company, N.A., which
acts as transfer agent and registrar. The share register reflects only record owners of our shares. Swiss law does not recognize fractional
share interests.
Comparison of Swiss law and Delaware law
The Swiss laws applicable to Swiss corporations and their shareholders
differ from laws applicable to U.S. corporations and their shareholders. The following table summarizes significant differences in shareholder
rights pursuant to the provisions of the Code of Obligations, by which our Company is governed, and the Delaware General Corporation
Law applicable to companies incorporated in Delaware and their shareholders. Please note that this is only a general summary of certain
provisions applicable to companies in Delaware. Certain Delaware companies may be permitted to exclude certain of the provisions
summarized below in their charter documents.
DELAWARE CORPORATE LAW |
SWISS CORPORATE LAW |
Mergers and similar arrangements |
Under the Delaware General Corporation Law, with certain exceptions, a merger, consolidation, sale, lease or transfer of all or substantially all of the assets of a corporation must be approved by the board of directors and a majority of the outstanding shares entitled to vote thereon. A shareholder of a Delaware corporation participating in certain major corporate transactions may, under certain circumstances, be entitled to appraisal rights pursuant to which such shareholder may receive cash in the amount of the fair value of the shares held by such shareholder (as determined by a court) in lieu of the consideration such shareholder would otherwise receive in the transaction. The Delaware General Corporation Law also provides that a parent corporation, by resolution of its board of directors, may merge with any subsidiary, of which it owns at least 90.0% of each class of capital stock without a vote by the shareholders of such |
Under Swiss law, with certain exceptions, a merger or a demerger of the corporation or a sale of all or substantially all of the assets of a corporation must be approved by two-thirds of the voting rights represented at the respective general meeting of shareholders as well as the majority of the par value of shares represented at such general meeting of shareholders. A shareholder of a Swiss corporation participating in a statutory merger or demerger pursuant to the Swiss Merger Act (Loi sur la fusion) can file a lawsuit against the surviving company. If the consideration is deemed “inadequate,” such shareholder may, in addition to the consideration (be it in shares or in cash) receive an additional amount to ensure that such shareholder receives the fair value of the shares held by such shareholder. Swiss law also provides that if the merger agreement |
DELAWARE CORPORATE LAW |
SWISS CORPORATE LAW |
|
|
subsidiary. Upon any such merger, dissenting shareholders of the subsidiary would have appraisal rights. |
provides only for a compensation payment, at least 90% of all members in the transferring legal entity
who are entitled to vote shall approve the merger agreement. |
Class actions and derivative actions generally are available to shareholders of a Delaware corporation for, among other things, breach of fiduciary duty, corporate waste and actions not taken in accordance with applicable law. In such actions, the court has discretion to permit the winning party to recover attorneys’ fees incurred in connection with such action. |
Class actions and derivative actions as such are not available
under Swiss law. Nevertheless, certain actions may have a similar effect. A shareholder is entitled to bring suit against directors,
officers or liquidators for breach of their duties and claim the payment of the company’s losses or damages to the corporation
and, in some cases, to the individual shareholder. Likewise, an appraisal lawsuit won by a shareholder may indirectly compensate
all shareholders. In addition, to the extent that U.S. laws and regulations provide a basis for liability and U.S. courts have
jurisdiction, a class action may be available.
Under Swiss law, the winning party is generally entitled to recover
a limited amount of attorneys’ fees incurred in connection with such action. The court has discretion to permit the shareholder
who lost the lawsuit to recover attorneys’ fees incurred to the extent that he or she acted in good faith.
|
Shareholder vote on board and management compensation |
Under the Delaware General Corporation Law, the board of directors has the authority to fix the compensation of directors, unless otherwise restricted by the certificate of incorporation or bylaws. |
Pursuant to Swiss law, the general meeting of shareholders has the non-transferable right, amongst others, to vote separately and bindingly on the maximum aggregate amount of compensation of the members of the board of directors, of the executive committee and of any advisory board. |
|
|
Annual vote on board renewal |
|
Unless directors are elected by written consent in lieu of an annual
meeting, directors are elected in an annual meeting of shareholders on a date and at a time designated by or in the manner provided in
the bylaws. Re-election is possible.
Classified boards are permitted.
|
The general meeting of shareholders elects the members of the board of directors, the chairperson of the board of directors and the members of the compensation committee individually and annually for a term of office until the end of the following general meeting of shareholders. Re-election is possible. |
Indemnification of directors and executive officers and limitation of liability |
The Delaware General Corporation Law provides that a certificate
of incorporation may contain a provision eliminating or limiting the personal liability
|
Under Swiss corporate law, an indemnification by the corporation
of a director or member of the executive committee in relation to potential
|
DELAWARE CORPORATE LAW |
SWISS CORPORATE LAW |
|
|
of directors and officers of the corporation for
monetary damages for breach of a fiduciary duty as a director or officer, except no provision in the certificate of incorporation may
eliminate or limit:
·
the
liability of a director or officer for any breach of the duty of loyalty to the corporation or its shareholder
·
the
liability of a director or officer for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation
of law;
·
a director’s
statutory liability for unlawful payment of dividends or unlawful share purchase or redemption;
·
the
liability of a director or officer for any transaction from which the director or officer derived an improper personal benefit; or
·
the
liability of an officer in any action by or in the right of the corporation.
A Delaware corporation may indemnify any person who was or is a party
or is threatened to be made a party to any proceeding, other than an action by or on behalf of the corporation, because the person is
or was a director or officer, against liability incurred in connection with the proceeding if the director or officer acted in good faith
and in a manner reasonably believed to be in, or not opposed to, the best interests of the corporation; and the director or officer, with
respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful.
Unless ordered by a court, any foregoing indemnification is subject
to a determination that the director or officer has met the applicable standard of conduct
·
by a
majority vote of the directors who are not parties to the proceeding, even though less than a quorum;
·
by a
committee of directors designated by a majority vote of the eligible directors, even though less than a quorum;
·
by independent
legal counsel in a written opinion if there are no eligible directors or if the eligible directors so direct; or
|
personal liability is not effective to the extent
the director or member of the executive committee intentionally or negligently violated his or her corporate duties towards
the corporation (certain views advocate that at least a grossly negligent violation is required to exclude the indemnification).
Furthermore, the general meeting of shareholders may discharge (release) the directors and members of the executive committee
from liability for their conduct to the extent the respective facts are known to shareholders. Such discharge is effective only
with respect to claims of the company and of those shareholders who approved the discharge or who have since acquired their
shares in full knowledge of the discharge. Most violations of corporate law are regarded as violations of duties towards the
corporation rather than towards the shareholders. In addition, indemnification of other controlling persons is not permitted
under Swiss corporate law, including shareholders of the corporation.
The articles of association of a Swiss corporation may also set
forth that the corporation shall indemnify and hold harmless, to the extent permitted by the law, the directors and executive
managers out of assets of the corporation against threatened, pending or completed actions.
Also, a corporation may enter into and pay for directors’
and officers’ liability insurance, which may cover negligent acts as well.
|
DELAWARE CORPORATE LAW |
SWISS CORPORATE LAW |
|
|
·
by the
shareholders.
Moreover, a Delaware corporation may not indemnify a director or
officer in connection with any proceeding in which the director or officer has been adjudged to be liable to the corporation unless and
only to the extent that the court determines that, despite the adjudication of liability but in view of all the circumstances of the
case, the director or officer is fairly and reasonably entitled to indemnity for those expenses which the court deems proper. |
|
Directors’ fiduciary duties |
A director of a Delaware corporation has a fiduciary duty to the corporation
and its shareholders. This duty has two components:
·
the
duty of care; and
·
the
duty of loyalty.
The duty of care requires that a director act in good faith, with the
care that an ordinarily prudent person would exercise under similar circumstances. Under this duty, a director must inform himself or
herself of, and disclose to shareholders, all material information reasonably available regarding a significant transaction.
The duty of loyalty requires that a director act in a manner he or she
reasonably believes to be in the best interests of the corporation. He or she must not use his or her corporate position for personal
gain or advantage. This duty prohibits self-dealing by a director and mandates that the best interest of the corporation and its shareholders
take precedence over any interest possessed by a director, officer or controlling shareholder and not shared by the shareholders generally.
In general, actions of a director are presumed to have been made on an informed basis, in good faith and in the honest belief that the
action taken was in the best interests of the corporation. However, this presumption may be rebutted by evidence of a breach of one of
the fiduciary duties.
Should such evidence be presented concerning a transaction by a director,
a director must prove the procedural fairness of the transaction and that the transaction was of fair value to the corporation.
|
The board of directors of a Swiss corporation manages the business of
the corporation, unless responsibility for such management has been duly delegated to the executive committee based on organizational
rules. However, there are several non-transferable duties of the board of directors:
·
the
overall management of the corporation and the issuing of all necessary directives;
· determination
of the corporation’s organization;
· the
organization of the accounting, financial control and financial planning systems as required for management of the corporation;
· the
appointment and dismissal of persons entrusted with managing and representing the corporation;
· overall
supervision of the persons entrusted with managing the corporation, in particular with regard to compliance with the law, articles of
association, operational regulations and directives;
· compilation
of the annual report, preparation for the general meeting of the shareholders, the compensation report, any other reports required by
the law or the articles of association and implementation of its resolutions; and
· the
filing an application for a debt restructuring moratorium and |
DELAWARE CORPORATE LAW |
SWISS CORPORATE LAW |
|
|
|
notification of the court in the event that the company is over-indebted.
The members of the board of directors must perform their duties with
all due diligence and safeguard the interests of the corporation in good faith. They must afford the shareholders equal treatment in equal
circumstances.
The duty of care requires that a director act in good faith, with the
care that an ordinarily prudent director would exercise under like circumstances.
The members of the board of directors and the executive committee are
required to immediately and fully inform the board of directors about conflicts of interests concerning them. The board of directors is
furthermore required to take measures in order to protect the interests of the company.
The duty of loyalty requires that a director safeguard the interests
of the corporation and requires that directors act in the interest of the corporation and, if necessarily, put aside their own interests.
If there is a risk of a conflict of interest, the board of directors must take appropriate measures to ensure that the interests of the
company are duly taken into account.
The burden of proof for a violation of these duties is with the corporation
or with the shareholder bringing a suit against the director.
The Swiss Federal Supreme Court has established a doctrine that restricts
its review of a business decision if the decision has been taken following proper preparation, on an informed basis and without conflicts
of interest.
|
Shareholder action by written consent |
A Delaware corporation may, in its certificate of incorporation, eliminate the right of shareholders to act by written consent. |
Shareholders of a Swiss corporation may exercise their voting rights in a general meeting of shareholders. Shareholders can only act by written consent if no shareholder requests a general meeting of shareholders. The articles of association must allow for an independent proxy to be present at a general meeting of shareholders. The instruction of such independent proxy may occur in writing or electronically. |
DELAWARE CORPORATE LAW |
SWISS CORPORATE LAW |
|
|
A shareholder of a Delaware corporation has the right to put any proposal before the annual meeting of shareholders, provided it complies with the notice provisions in the governing documents. A special meeting may be called by the board of directors or any other person authorized to do so in the governing documents, but shareholders may be precluded from calling special meetings. |
At any general meeting of shareholders any shareholder may put proposals
to the meeting if the proposal is part of an agenda item. No resolution may be taken on proposals relating to the agenda items that were
not duly notified.
Unless the articles of association provide for a lower threshold or
for additional shareholders’ rights:
·
shareholders
together representing at least 5% of the share capital or voting rights may demand that a general meeting of shareholders be called for
specific agenda items and specific proposals; and
·
shareholders
together representing at least 0.5% of the share capital or voting rights may demand that an agenda item including a specific proposal,
or a proposal with respect to an existing agenda item, be put on the agenda for a scheduled general meeting of shareholders, provided
such request is made with appropriate lead time.
Any shareholder can propose candidates for election as directors or
make other proposals within the scope of an agenda item without prior written notice.
In addition, any shareholder is entitled, at a general meeting of shareholders
and without advance notice, to (i) request information from the board of directors on the affairs of the company (note, however, that
the right to obtain such information is limited), (ii) request information from the auditors on the methods and results of their audit,
(iii) request that the general meeting of shareholders resolve to convene an extraordinary general meeting, or (iv) request that the general
meeting of shareholders resolve to appoint an examiner to carry out a special examination (“examen spécial”).
|
Cumulative voting |
Under the Delaware General Corporation Law, cumulative voting for elections of directors is not |
Cumulative voting is not permitted under Swiss corporate law. Pursuant to Swiss law, shareholders can vote for each proposed candidate, but they are not allowed to cumulate |
DELAWARE CORPORATE LAW |
SWISS CORPORATE LAW |
|
|
permitted unless the corporation’s certificate of incorporation provides for it. |
their votes for single candidates. An annual individual election of (i) all members of the board of directors, (ii) the chairperson of the board of directors, (iii) the members of the compensation committee, (iv) the election of the independent proxy for a term of office of one year (i.e., until the following annual general meeting of shareholders), as well as the vote on the maximum aggregate amount of compensation of the members of the board of directors, of the executive committee and of the members of any advisory board, is mandatory for listed companies. Re-election is permitted. |
|
|
A Delaware corporation with a classified board may be removed only for cause with the approval of a majority of the outstanding shares entitled to vote, unless the certificate of incorporation provides otherwise. |
A Swiss corporation may remove, with or without cause, any director at any time with a resolution passed by a majority of the shares represented at a general meeting of shareholders. The articles of association may require the approval by a supermajority of the shares represented at a meeting for the removal of a director. |
Transactions with interested shareholders |
The Delaware General Corporation Law generally prohibits a Delaware corporation from engaging in certain business combinations with an “interested shareholder” for three years following the date that such person becomes an interested shareholder. An interested shareholder generally is a person or group who or which owns or owned 15.0% or more of the corporation’s outstanding voting shares within the past three years. |
No such rule applies to a Swiss corporation. |
Unless the board of directors of a Delaware corporation approves the proposal to dissolve, dissolution must be approved by shareholders holding 100.0% of the total voting power of the corporation. Only if the dissolution is initiated by the board of directors may it be approved by a simple majority of the corporation’s outstanding shares. Delaware law allows a Delaware corporation to include in its certificate of incorporation a supermajority voting requirement in connection with dissolutions initiated by the board. |
A dissolution of a Swiss corporation requires the approval by two-thirds of the voting rights represented at the respective general meeting of shareholders as well as the majority of the par value of shares represented at such general meeting of shareholders. The articles of association may increase the voting thresholds required for such a resolution. |
|
|
Variation of rights of shares |
|
A Delaware corporation may vary the rights of a class of shares with the approval of a majority of the |
The general meeting of shareholders of a Swiss corporation may
resolve that preference shares |
DELAWARE CORPORATE LAW |
SWISS CORPORATE LAW |
|
|
outstanding shares of such class, unless the certificate of incorporation provides otherwise. |
be issued or that existing shares be converted into preference shares with a resolution passed by a majority of
the shares represented at the general meeting of shareholders. Where a company has issued preference shares, further preference shares
conferring preferential rights over the existing preference shares may be issued only with the consent of both a special meeting of the
adversely affected holders of the existing preference shares and of a general meeting of all shareholders, unless otherwise provided in
the articles of association.
Shares with preferential voting rights are not regarded as preference
shares for these purposes.
|
Amendment of governing documents |
|
A Delaware corporation’s governing documents may be amended with the approval of a majority of the outstanding shares entitled to vote, unless the certificate of incorporation provides otherwise. |
The articles of association of a Swiss corporation may be amended with
a resolution passed by a majority of the shares represented at a general meeting of shareholders, unless otherwise provided in the articles
of association.
There are a number of resolutions, such as an amendment of the stated
purpose of the corporation, the introduction of a capital range and conditional capital and the introduction of shares with preferential
voting rights that require the approval by two-thirds of the votes and a majority of the par value of the shares represented at such general
meeting of shareholders. The articles of association may increase these voting thresholds. The articles of association of a Swiss corporation
may be amended with a resolution passed by a majority of the shares represented at a general meeting of shareholders, unless otherwise
provided in the articles of association.
|
Inspection of books and records |
|
Shareholders of a Delaware corporation, upon written demand under oath stating the purpose thereof, have the right during the usual hours for business to inspect for any proper purpose and to obtain copies of list(s) of shareholders and other books and records of the corporation and its subsidiaries, if any, to the extent the books and records of such subsidiaries are available to the corporation. |
Shareholders of a Swiss corporation holding in the aggregate at
least 5% of the nominal share capital or voting rights have the right to inspect books and records, subject to the safeguarding
of the company’s business secrets and other interests warranting protection. A shareholder is only entitled to receive information
to the extent required to exercise his or her rights as a shareholder. The board of directors has to decide on an inspection
request within four months after receipt of such request. Denial of the request will need to be justified in writing. If |
DELAWARE CORPORATE LAW |
SWISS CORPORATE LAW |
|
|
|
the board of
directors denies an inspection request, shareholders may request the order of an inspection by the court within thirty days.
A shareholder’s right to inspect the share register is limited
to the right to inspect his or her own entry in the share register.
|
The board of directors may approve a dividend without shareholder approval.
Subject to any restrictions contained in its certificate of incorporation, the board may declare and pay dividends upon the shares of
its capital stock either:
· out
of its surplus; or
· in
case there is no such surplus, out of its net profits for the fiscal year in which the dividend is declared and/or the preceding fiscal
year.
Shareholder approval is required to authorize capital stock in excess
of that provided in the charter. Directors may issue authorized shares without shareholder approval.
|
Dividend (including interim dividend) payments are subject to the approval
of the general meeting of shareholders. The board of directors may propose to shareholders that a dividend shall be paid but cannot itself
authorize the distribution.
Payments out of a corporation’s share capital (in other words,
the aggregate par value of the corporation’s shares) in the form of dividends are not allowed and may be made only by way of a share
capital reduction. Dividends (including interim dividends) may be paid only from the profits of the previous business year or brought
forward from previous or current business years or if the corporation has distributable reserves, each as evidenced by the corporation’s
audited stand-alone statutory balance sheet prepared pursuant to Swiss law and after allocations to reserves required by Swiss law and
the articles of association have been deducted.
|
Creation and issuance of new shares |
|
All creation of shares require the board of directors to adopt a resolution or resolutions, pursuant to authority expressly vested in the board of directors by the provisions of the company’s certificate of incorporation. |
All creation of shares require a shareholders’ resolution. The creation of a capital range or conditional share capital requires at least two-thirds of the voting rights represented at the general meeting of shareholders and a majority of the par value of shares represented at such meeting. The board of directors may issue or cancel shares out of the capital range during a period of up to five years by a maximum amount of 50% of the current share capital. Shares are created and issued out of conditional share capital through the exercise of options or of conversion rights that the board of directors may grant to shareholders, creditors of bonds or similar debt instruments, employees, directors of the company or another group company or third parties. |
TAXATION
The following discussion is based on the tax laws, regulations and regulatory
practices of Switzerland and the United States as in effect on the date hereof, which are subject to change (or subject to changes in
interpretation), possibly with retroactive effect.
Current and prospective shareholders are advised to consult their own
tax advisers in light of their particular circumstances as to the Swiss or U.S. tax laws, regulations and regulatory practices that could
be relevant for them in connection with owning and selling or otherwise disposing of our ordinary shares and receiving dividends and similar
cash or in-kind distributions on our ordinary shares (including dividends on liquidation proceeds and share dividends) or distributions
on our ordinary shares based upon a capital reduction or reserves paid out of capital contributions and the consequences thereof under
the tax laws, regulations and regulatory practices of Switzerland or the United States.
Swiss Tax Considerations
Withholding Tax
Under present Swiss tax law, dividends due and similar cash or in-kind
distributions made by the Company to a shareholder of ordinary shares (including liquidation proceeds and bonus shares) are subject to
Swiss federal withholding tax (“Withholding Tax”), currently at a rate of 35% (applicable to the gross amount of taxable distribution).
However, the repayment of the par value of the ordinary shares and any repayment of qualifying additional paid-in capital (capital contribution
reserves), within the limitations accepted by the legislation in force when such Dividend becomes due and the respective administrative
practice, are not subject to the Withholding Tax. The Company is obliged to deduct any applicable Withholding Tax from the gross amount
of any taxable distribution and to pay the tax to the Swiss Federal Tax Administration within 30 days of the due date of such distribution.
Swiss resident individuals who hold their ordinary shares as private
assets (“Resident Private Shareholders”) are in principle eligible for a full refund or credit against income tax of the Withholding
Tax if they duly report the underlying income in their income tax return. In addition, (i) corporate and individual shareholders
who are resident in Switzerland for tax purposes, (ii) corporate and individual shareholders who are not resident in Switzerland,
and who, in each case, hold their ordinary shares as part of a trade or business carried on in Switzerland through a permanent establishment
with fixed place of business situated in Switzerland for tax purposes and (iii) Swiss resident private individuals who, for income
tax purposes, are classified as “professional securities dealers” for reasons of, inter alia, frequent dealing, or leveraged
investments, in shares and other securities (collectively, “Domestic Commercial Shareholders”) are in principle eligible for
a full refund or credit against income tax of the Withholding Tax if they duly report the underlying income in their statements of operations
or income tax return, as the case may be.
Shareholders who are not resident in Switzerland for tax purposes, and
who, in each case and during the respective taxation year, do not hold their ordinary shares as part of a trade or business carried on
through a permanent establishment with fixed place of business situated in Switzerland for tax purposes, and who are not subject to corporate
or individual income taxation in Switzerland for any other reason (collectively, “Non-Resident Shareholders”) may be entitled
to a total or partial refund of the Withholding Tax if the country in which such recipient resides for tax purposes maintains a bilateral
treaty for the avoidance of double taxation with Switzerland and further conditions of such treaty are met. Non-Resident Shareholders
should be aware that the procedures for claiming treaty benefits (and the time required for obtaining a refund) may differ from country
to country. Non-Resident Shareholders should consult their own legal, financial or tax advisors regarding receipt, ownership, purchases,
sale or other dispositions of ordinary shares and the procedures for claiming a refund of the Withholding Tax.
Swiss Federal Issuance Stamp Duty
The Company will be subject to the Swiss federal issuance stamp duty
(droit de timbre d’émission) on the issuance of ordinary shares of 1% of the offering price, net of certain deductions.
Swiss Federal Securities Transfer Tax
The delivery of ordinary shares against payment of the offering price
is not subject to Swiss securities transfer tax (droit de timbre de négociation). Any subsequent transactions in ordinary
shares in the secondary markets are subject to Swiss securities transfer tax at an aggregate rate of 0.15% of the consideration paid for
such ordinary shares, however, only if a bank or other securities dealer in Switzerland, as defined in the Swiss Federal Stamp Tax Act
(loi fédérale sur les droits de timbre), is a party or an intermediary to the transaction and no exemption applies.
Swiss Federal, Cantonal and Communal Individual Income Tax
and Corporate Income Tax
Non-Resident Shareholders
Non-Resident Shareholders are not subject to any Swiss federal, cantonal
or communal income tax on dividend payments and similar distributions because of the mere holding of ordinary shares. The same applies
for capital gains on the sale of ordinary shares subject to certain exceptions. For Withholding Tax consequences, see “—Swiss
Tax Considerations—Withholding Tax.”
Resident Private Shareholders and Domestic Commercial Shareholders
Resident Private Shareholders who receive dividends and similar cash
or in-kind distributions (including liquidation proceeds as well as bonus shares or taxable repurchases of ordinary shares as described
above), which are not repayments of the par value of ordinary shares or, within the limitations accepted by the legislation in force and
the respective administrative practice, qualifying additional paid-in capital (capital contribution reserves), are required to report
such receipts in their individual income tax returns and are subject to Swiss federal, cantonal and communal income tax on any net taxable
income for the relevant tax period. A gain or a loss by Resident Private Shareholders realized upon the sale or other disposition of ordinary
shares to a third party will generally be a tax-free private capital gain or a non-tax-deductible capital loss, as the case may be. Under
exceptional circumstances the capital gain may be re-characterized into a taxable dividend, in particular upon taxable repurchase of ordinary
shares as described above. When a capital gain is re-characterized as a dividend, the relevant income for tax purposes corresponds to
the difference between the repurchase price and the sum of the par value of ordinary shares and, within the limitations accepted by the
legislation in force and the respective administrative practice, qualifying additional paid-in capital (capital contribution reserves).
Domestic Commercial Shareholders who receive dividends and similar cash
or in-kind distributions (including liquidation proceeds as well as bonus shares) are required to recognize such payments in their statements
of operations for the relevant tax period and are subject to Swiss federal, cantonal and communal individual or corporate income tax,
as the case may be, on any net taxable earnings accumulated (including the dividends) for such period. Domestic Commercial Shareholders
who are corporate taxpayers may qualify for participation relief on dividend distributions (réduction pour participations),
if ordinary shares held have an aggregate market value of at least CHF 1 million or represent 10% or more of our share capital. For
cantonal and communal income tax purposes, the regulations on participation relief are broadly similar, depending on the canton of residency.
Domestic Commercial Shareholders are required to recognize a gain or
loss realized upon the disposal of ordinary shares in their statement of operations for the respective taxation period and are subject
to Swiss federal, cantonal and communal individual or corporate income tax, as the case may be, on any net taxable earnings (including
the gain or loss realized on the sale or other disposition of ordinary shares) for such taxation period.
Swiss Wealth Tax and Capital Tax
Non-Resident Shareholders
Non-Resident Shareholders holding ordinary shares are not subject to
cantonal and communal wealth or annual capital tax because of the mere holding of ordinary shares.
Resident Private Shareholders
Resident Private Shareholders are required to report their ordinary
shares as part of their private assets and are subject to cantonal and communal wealth tax.
Domestic Commercial Shareholders
Domestic Commercial Shareholders are required to report their ordinary
shares as part of their business assets or taxable capital, as defined, and are subject to cantonal and communal wealth or annual capital
tax.
Automatic Exchange of Information in Tax Matters
On November 19, 2014, Switzerland signed the Multilateral Competent
Authority Agreement. The Multilateral Competent Authority Agreement is based on Article 6 of the OECD/Council of Europe administrative
assistance convention and is intended to ensure the uniform implementation of Automatic Exchange of Information (the “AEOI”).
The Federal Act on the International Automatic Exchange of Information in Tax Matters (the “AEOI Act”) entered into force
on January 1, 2017. The AEOI Act is the legal basis for the implementation of the AEOI standard in Switzerland.
The AEOI is being introduced in Switzerland through bilateral agreements
or multilateral agreements. The agreements have been, and will be, concluded on the basis of guaranteed reciprocity, compliance with the
principle of speciality (i.e., the information exchanged may only be used to assess and levy taxes (and for criminal tax proceedings))
and adequate data protection.
Based on such multilateral or bilateral agreements and the implementation
of Swiss law, Switzerland collects and exchanges data in respect of financial assets, including ordinary shares, held in, and income derived
thereon and credited to, accounts or deposits with a paying agent in Switzerland for the benefit of individuals resident in a European
Union member state or in a treaty state.
Swiss Facilitation of the Implementation of the U.S. Foreign
Account Tax Compliance Act
Switzerland has concluded an intergovernmental agreement with the United
States to facilitate the implementation of U.S. Foreign Account Tax Compliance Act. The agreement ensures that the accounts held by U.S.
persons with Swiss financial institutions are disclosed to the U.S. tax authorities either with the consent of the account holder or by
means of group requests within the scope of administrative assistance. Information will not be transferred automatically in the absence
of consent, and instead will be exchanged only within the scope of administrative assistance on the basis of the double taxation agreement
between the United States and Switzerland. On October 8, 2014, the Swiss Federal Council approved a mandate for negotiations with
the United States on changing the current direct-notification-based regime to a regime where the relevant information is sent to the Swiss
Federal Tax Administration, which in turn provides the information to the U.S. tax authorities.
Material U.S. Federal Income Tax Consequences
for U.S. Holders
The following is a description of the material U.S. federal income tax
consequences to U.S. Holders (as defined below) of owning and disposing of our ordinary shares. It does not describe all tax consequences
that may be relevant to a particular person’s decision to acquire ordinary shares.
This discussion applies only to a U.S. Holder that holds ordinary shares
as “capital assets” for U.S. federal income tax purposes within the meaning of Section 1221 of the Internal Revenue Code of
1986, as amended (the “Code”) (generally, property held for investment). In addition, it does not describe any tax consequences
other than U.S. federal income tax consequences, including state and local tax consequences and estate or gift tax consequences, and does
not describe all of the U.S. federal income tax consequences that may be relevant in light of the U.S. Holder’s particular circumstances,
including alternative minimum tax consequences, the special tax accounting rules under Section 451(b) of the
Code, the potential application of the Medicare contribution tax on
net investment income, and tax consequences applicable to U.S. Holders subject to special rules, such as:
| · | certain banks, insurance companies and other financial institutions; |
| · | brokers, dealers or traders in securities who use a mark-to-market method of tax accounting; |
| · | persons holding ordinary shares as part of a straddle, wash sale, conversion transaction or other integrated transaction or persons
entering into a constructive sale with respect to the ordinary shares; |
| · | persons whose functional currency for U.S. federal income tax purposes is not the U.S. dollar; |
| · | entities or arrangements classified as partnerships or S corporations for U.S. federal income tax purposes and investors in such entities; |
| · | tax-exempt entities, including an “individual retirement account” or “Roth IRA” or governmental entities; |
| · | corporations that accumulate earnings to avoid U.S. federal income tax; |
| · | real estate investment trusts or regulated investment companies; |
| · | former U.S. citizens or long-term residents of the United States; |
| · | persons that own or are deemed to own 10% or more of the voting power or value of our shares; or |
| · | persons holding ordinary shares in connection with a trade or business conducted outside of the United States or in connection with
a permanent establishment or other fixed place of business outside of the United States. |
If an entity or arrangement that is classified as a partnership for
U.S. federal income tax purposes holds ordinary shares, the U.S. federal income tax treatment of a partner will generally depend on the
status of the partner and the activities of the partnership. Partnerships holding ordinary shares and partners in such partnerships should
consult their tax advisers as to the particular U.S. federal income tax consequences of owning and disposing of the ordinary shares in
their particular circumstances.
This discussion is based on the Code, administrative pronouncements,
judicial decisions, final, temporary and proposed Treasury regulations, and the income tax treaty between Switzerland and the United States
(the “Treaty”), all as of the date hereof, any of which is subject to change or differing interpretations, possibly with retroactive
effect.
A “U.S. Holder” is a holder who, for U.S. federal income
tax purposes, is a beneficial owner of ordinary shares who is eligible for the benefits of the Treaty and who is:
| · | an individual who is a citizen or resident of the United States; |
| · | a corporation, or other entity taxable as a corporation, created or organized in or under the laws of the United States, any state
therein or the District of Columbia; or |
| · | an estate or trust, the income of which is subject to U.S. federal income taxation regardless of its source. |
U.S. Holders should consult their tax advisers concerning the U.S. federal,
state, local and non-U.S. tax consequences of owning and disposing of ordinary shares in their particular circumstances.
Treasury regulations that apply to taxable years beginning on or after
December 28, 2021 (the “Foreign Tax Credit Regulations”), may in some circumstances prohibit a U.S. person from claiming a
foreign tax credit with respect to certain non-U.S. taxes that are not creditable under applicable income tax treaties. Accordingly, U.S.
investors that are not eligible for Treaty benefits should consult their tax advisers regarding the creditability or deductibility of
any Swiss taxes imposed on dividends on, or dispositions of, the ordinary shares. The discussions below regarding the creditability or
deductibility of Swiss taxes, if any, do not apply to investors in this special situation.
Passive Foreign Investment Company Rules
Under the Code, we will be a PFIC for any taxable year in which, after
the application of certain “look-through” rules with respect to subsidiaries, either (i) 75% or more of our gross income consists
of “passive income,” or (ii) 50% or more of the average quarterly value of our assets consists of assets that produce, or
are held for the production of, “passive income.” For purposes of the above calculations, we will be treated as if we hold
our proportionate share of the assets of, and receive directly our proportionate share of the income of, any other corporation in which
we directly or indirectly own at least 25%, by value, of the shares of such corporation. Passive income generally includes dividends,
interest, rents, certain non-active royalties and capital gains.
Cash is generally characterized as a passive asset for these purposes.
Goodwill, which is defined as the difference between our market capitalization and our net assets, is generally characterized as a non-passive
or passive asset based on the nature of the income produced in the activity to which the goodwill is attributable. Additionally, the extent
to which our goodwill should be characterized as a non-passive asset is not entirely clear. We hold a substantial amount of cash, which
is generally characterized as a passive asset, and while this continues to be the case our PFIC status for any taxable year depends largely
on the value of our goodwill and the characterization of our goodwill as passive or non-passive. The value of our goodwill for any taxable
year may be determined in large part by reference to the average of our market capitalization for that year. Because our market capitalization
declined substantially during 2022, we believe we were a PFIC for our 2022 taxable year. Due to our current market capitalization, there
is a risk that we will also be a PFIC for 2023 and possibly future taxable years. We have not obtained any valuation of our assets (including
goodwill). U.S. Holders in our ordinary shares should consult their tax advisers regarding the value and characterization of our assets
for purposes of the PFIC rules, which are subject to some uncertainties. In addition, our PFIC status is a factual annual determination
that can be made only after the end of the relevant taxable year and will depend on the composition of our income and assets and the value
of our assets from time to time. Accordingly, our PFIC status for 2023 and any future taxable year is uncertain.
If we are a PFIC for any year during which a U.S. Holder holds ordinary
shares, we would generally continue to be treated as a PFIC with respect to such holder for all succeeding years during which such holder
holds ordinary shares, even if we ceased to meet the threshold requirements for PFIC status. If we were a PFIC for any taxable year and
any of our subsidiaries or other companies in which we owned or were treated as owning equity interests were also a PFIC (any such entity,
a “Lower-tier PFIC”), a U.S. Holder would be deemed to own a proportionate amount (by value) of the shares of each Lower-tier
PFIC and would be subject to U.S. federal income tax according to the rules described in the subsequent paragraph on (i) certain distributions
by a Lower-tier PFIC and (ii) dispositions of shares of Lower-tier PFICs, in each case as if such holder held such shares directly, even
though such holder will not have received the proceeds of those distributions or dispositions.
If we are a PFIC for any taxable year during which a U.S. Holder holds
any of our ordinary shares, such holder will generally be subject to adverse tax consequences. Unless a U.S. Holder makes a timely “mark
to market” election or “qualified electing fund” ("QEF") election, each as discussed below, gain recognized
upon a disposition (including, under certain circumstances, a pledge) of ordinary shares will be allocated ratably over a U.S. Holder’s
holding period for the ordinary shares. The amounts allocated to the taxable year of disposition and to years before we became a PFIC
will be taxed as ordinary income. The amount allocated to each other taxable year will be subject to tax at the highest rate in effect
for that taxable year for individuals or corporations, as appropriate, and an interest charge will be imposed on the tax on such amount.
Further, to the extent that any distributions received on a U.S. Holder’s ordinary shares during a
taxable year exceed 125% of the average of the annual distributions
on those shares during the preceding three years or such holder’s holding period, whichever is shorter, those distributions will
be subject to taxation in the same manner as gain, described immediately above.
Alternatively, if we are a PFIC and if the ordinary shares are “regularly
traded” on a “qualified exchange,” a U.S. Holder will be eligible to make a mark-to-market election that will result
in tax treatment different from the general tax treatment for PFICs described above. The ordinary shares will be treated as “regularly
traded” if more than a de minimis amount of the ordinary shares are traded on a qualified exchange on at least 15 days during each
calendar quarter (the “15-Day Test”). The Nasdaq, on which the ordinary shares are listed, is a qualified exchange for this
purpose. Once made, the election cannot be revoked without the consent of the IRS unless the shares cease to be marketable.
If a U.S. Holder makes the mark-to-market election, such holder will
generally recognize as ordinary income any excess of the fair market value of such holder’s ordinary shares at the end of each taxable
year over their adjusted tax basis, and will recognize an ordinary loss in respect of any excess of the adjusted tax basis of the ordinary
shares over their fair market value at the end of the taxable year (but only to the extent of the net amount of income previously included
as a result of the mark-to-market election). If a U.S. Holder makes the election, such holder’s tax basis in their ordinary shares
will be adjusted to reflect these income or loss amounts. Any gain recognized on the sale or other disposition of ordinary shares in a
year when we are a PFIC will be treated as ordinary income and any loss will be treated as an ordinary loss (but only to the extent of
the net amount of income previously included as a result of the mark-to-market election). This election will not apply to any of our non-U.S.
subsidiaries. Accordingly, a U.S. Holder may continue to be subject to tax under the PFIC excess distribution regime with respect to any
Lower-tier PFICs notwithstanding a mark-to-market election for the ordinary shares.
In addition, if we are a PFIC for any taxable year in which we pay a
dividend or for the prior taxable year, the preferential dividend rates discussed above with respect to dividends paid to certain non-corporate
U.S. Holders will not apply.
If a company that is a PFIC provides certain information to U.S. Holders,
a U.S. Holder can then avoid certain adverse tax consequences described above by making a QEF election to be taxed currently on its proportionate
share of the PFIC’s ordinary income and net capital gains.
The QEF election is made on a shareholder-by-shareholder basis and,
once made, can be revoked only with the consent of the IRS. A U.S. Holder generally makes a QEF election by attaching a completed IRS
Form 8621, including the information provided in a PFIC Annual Information Statement, to a timely filed U.S. federal income tax return
for the taxable year to which the election relates. U.S. Holders should consult their tax adviser regarding the availability and tax consequences
of a retroactive QEF election under their particular circumstances. In order to comply with the requirements of a QEF election, a U.S.
Holder must receive a PFIC Annual Information Statement from us. We expect to provide information necessary for our U.S. investors to
make a QEF election with respect to us for the 2023 taxable year and any subsequent year if we believe we are a PFIC, but there is no
assurance that we will timely provide this information.
If a U.S. Holder owns ordinary shares during any year in which we are
a PFIC, such holder must generally file annual reports containing such information as the U.S. Treasury may require on IRS Form 8621 (or
any successor form) with respect to us, generally with such holder’s federal income tax return for that year.
The rules dealing with PFICs and with the mark-to-market and QEF elections
are complex and are affected by various factors in addition to those described above. Accordingly, U.S. Holders should consult their tax
advisers concerning the application of the PFIC rules to our ordinary share under their particular circumstances.
Information Returns
If a U.S. Holder owns ordinary shares during any year in which we are
a PFIC or in which we hold a direct or indirect equity interest in a Lower-tier PFIC, the U.S. Holder generally must file an annual report
on IRS Form 8621 with respect to each such PFIC containing such information as the U.S. Treasury may require, generally with the U.S.
Holder’s U.S. federal income tax return for the relevant year. A U.S. Holder’s failure to file the annual report will cause
the statute of limitations for such U.S. Holder’s U.S. federal income tax return to remain open with respect to the items required
to be included in such report until three years after the U.S. Holder files the annual report and, unless such failure is due to reasonable
cause and not willful neglect, the statute of limitations for the U.S. Holder’s entire U.S. federal income tax return will remain
open during such period.
PROSPECTIVE U.S. HOLDERS SHOULD CONSULT THEIR TAX ADVISORS REGARDING
THE CONSEQUENCES OF OUR POTENTIAL PFIC STATUS ON AN INVESTMENT IN ORDINARY SHARES.
Taxation of Distributions
The following is subject to the discussion regarding the PFIC rules
described above.
Distributions paid on ordinary shares, other than certain pro rata distributions
of ordinary shares, will generally be treated as dividends to the extent paid out of our current or accumulated earnings and profits (as
determined under U.S. federal income tax principles). Because we do not maintain calculations of our earnings and profits under U.S. federal
income tax principles, we expect that distributions generally will be reported to U.S. Holders as dividends. For so long as our ordinary
shares are listed on the NYSE or we are eligible for benefits under the Treaty, dividends paid to certain non-corporate U.S. Holders will
be eligible for taxation as “qualified dividend income” and therefore, subject to applicable holding period requirements,
will be taxable at rates not in excess of the long-term capital gain rate applicable to such U.S. Holder.
The amount of a dividend will include any amounts withheld by us in
respect of Swiss income taxes. The amount of the dividend will be treated as foreign-source dividend income to U.S. Holders and will not
be eligible for the dividends-received deduction generally available to U.S. corporations under the Code. Dividends will be included in
a U.S. Holder’s income on the date of the U.S. Holder’s receipt of the dividend. The amount of any dividend income paid in
Swiss francs will be the U.S. dollar amount calculated by reference to the exchange rate in effect on the date of actual or constructive
receipt, regardless of whether the payment is in fact converted into U.S. dollars at that time. If the dividend is converted into U.S.
dollars on the date of receipt, a U.S. Holder should not be required to recognize foreign currency gain or loss in respect of the dividend
income. A U.S. Holder may have foreign currency gain or loss if the dividend is converted into U.S. dollars after the date of receipt.
Such foreign currency gain or loss would generally be treated as U.S.-source ordinary income or loss.
Subject to applicable limitations, some of which vary depending upon
the U.S. Holder’s particular circumstances, Swiss income taxes withheld from dividends on ordinary shares (at a rate not exceeding
the rate provided by the Treaty) may be creditable against the U.S. Holder’s U.S. federal income tax liability. The rules governing
foreign tax credits are complex. For example, under the Foreign Tax Credit Regulations, in the absence of an election to apply the benefits
of the Treaty, in order for foreign income taxes to be creditable, the rules imposing the taxes must be consistent with certain U.S. federal
income tax principles, and we have not determined whether the Swiss income tax system meets all these requirements. U.S. Holders should
consult their tax advisers regarding the creditability of foreign taxes in their particular circumstances. In lieu of claiming a foreign
tax credit, U.S. Holders may, at their election, deduct foreign taxes, including any Swiss income tax, in computing their taxable income,
subject to generally applicable limitations under U.S. law. An election to deduct foreign taxes instead of claiming foreign tax credits
applies to all foreign taxes paid or accrued in the taxable year.
Sale or Other Disposition of Ordinary Shares
The following is subject to the discussion regarding the PFIC rules
described above.
Gain or loss realized by a U.S. Holder on the sale or other disposition
of ordinary shares will be capital gain or loss, and will be long-term capital gain or loss if the U.S. Holder’s holding period
for such ordinary shares was more than one year as of the date of the sale or other disposition. The amount of the gain or loss will equal
the difference between the U.S. Holder’s tax basis in the ordinary shares disposed of and the amount realized on the disposition,
in each case as determined in U.S. dollars. Long-term capital gain recognized by a non-corporate U.S. Holder is subject to U.S. federal
income tax at rates lower than the rates applicable to ordinary income and short-term capital gains, while short-term capital gains are
subject to U.S. federal income tax at the rates applicable to ordinary income. This gain or loss will generally be U.S.-source gain or
loss for foreign tax credit purposes. The deductibility of capital losses is subject to various limitations.
Information Reporting and Backup Withholding
Payments of dividends and sales proceeds that are made within the United
States or through certain U.S.-related financial intermediaries generally are subject to information reporting, and may be subject to
backup withholding, unless (i) the U.S. Holder is a corporation or other exempt recipient or (ii) in the case of backup withholding, the
U.S. Holder provides a correct taxpayer identification number and certifies that it is not subject to backup withholding.
Backup withholding is not an additional tax. The amount of any backup
withholding from a payment to a U.S. Holder will be allowed as a credit against the U.S. Holder’s U.S. federal income tax liability
and may entitle it to a refund, provided that the required information is timely furnished to the IRS.
Information with Respect to Foreign Financial Assets
Certain U.S. Holders who are individuals (and, under regulations, certain
entities) may be required to report information relating to an interest in our ordinary shares, subject to certain exceptions (including
an exception for ordinary shares held in accounts maintained by certain U.S. financial institutions), by filing IRS Form 8938 (Statement
of Specified Foreign Financial Assets) with their federal income tax return. Such U.S. Holders who fail to timely furnish the required
information may be subject to a penalty. Additionally, if a U.S. Holder does not file the required information, the statute of limitations
with respect to tax returns of the U.S. Holder to which the information relates may not close until three years after such information
is filed. U.S. Holders should consult their tax advisers regarding the effect, if any, of this legislation on their ownership and disposition
of the ordinary shares.
PLAN OF DISTRIBUTION
We entered into a sales agreement with Cowen and Company, LLC, or the
sales agent, under which we may offer and sell our ordinary shares from time to time through Cowen and Company, LLC, acting as agent.
Pursuant to this prospectus supplement and accompanying prospectus, we may offer and sell up to $50,000,000 of our ordinary shares. Sales
of our ordinary shares, if any, under this prospectus supplement and the accompanying prospectus will be made by any method that is deemed
to be an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act.
Each time we wish to issue and sell ordinary shares under the sales
agreement, we will notify the placement of the number of ordinary shares to be sold, the dates on which such sales are anticipated to
be made, any limitation on the number of ordinary shares to be sold in any one day and any minimum price below which sales may not be
made. Once we have so instructed the sales agent, unless it declines to accept the terms of such notice, the sales agent has agreed to
use its commercially reasonable efforts consistent with its normal trading and sales practices to sell such ordinary shares up to the
amount specified on such terms. The obligations of the sales agent under the sales agreement to sell our ordinary shares are subject to
a number of conditions that we must meet.
The settlement of sales of our ordinary shares between us and the sales
agent is generally anticipated to occur on the second trading day following the date on which the sale was made. Sales of our ordinary
shares as contemplated in this prospectus supplement will be settled through the facilities of The Depository Trust Company or by such
other means as we and the sales agent may agree upon. There is no arrangement for funds to be received in an escrow, trust or similar
arrangement.
We will pay the sales agent a commission up to 3.0% of the aggregate
gross proceeds we receive from each sale of our ordinary shares. Because there is no minimum offering amount required as a condition to
close this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time.
Except as we and the sales agent otherwise agree, we will reimburse the sales agent for the fees and disbursements of its counsel, payable
upon execution of the sales agreement, in an amount not to exceed $150,000, in addition to certain ongoing disbursements of its legal
counsel unless we and the sales agent otherwise agree.
We estimate that the total expenses for the offering, excluding any
commissions or expense reimbursement payable to the sales agent under the terms of the sales agreement, will be approximately $0.8 million.
The remaining proceeds, after deducting any other transaction fees, will equal our net proceeds from the sale of our ordinary shares in
this offering.
The sales agent will provide written confirmation to us before the open
on Nasdaq on the day following each day on which ordinary shares are sold under the sales agreement. Each confirmation will include the
number of ordinary shares sold on that day, the aggregate gross proceeds of such sales and the proceeds to us.
In connection with the sale of ordinary shares on our behalf, the sales
agent will be deemed to be an “underwriter” within the meaning of the Securities Act, and the compensation of the sales agent
will be deemed to be underwriting commissions or discounts. We have agreed to indemnify the sales agent against certain liabilities, including
civil liabilities under the Securities Act. We have also agreed to contribute to payments the sales agent may be required to make in respect
of such liabilities.
The offering of our ordinary shares pursuant to the sales agreement
will terminate upon the earlier of (i) the sale of all ordinary shares subject to the sales agreement and (ii) the termination of the
sales agreement as permitted therein.
This summary of the material provisions of the sales agreement does
not purport to be a complete statement of its terms and conditions. A copy of the sales agreement is filed as an exhibit to a Report on
Form 6-K filed under the Exchange Act and incorporated by reference in this prospectus supplement.
The sales agent and its affiliates may in the future provide various
investment banking, commercial banking, financial advisory and other financial services for us and our affiliates, for which services
they may in the future receive customary fees. In the course of its business, the sales agent may actively trade our securities for its
own account or for the accounts of customers, and, accordingly, the sales agent may at any time hold long or short positions in such securities.
A prospectus supplement and the accompanying prospectus in electronic
format may be made available on a website maintained by the sales agent, and the sales agent may distribute the prospectus supplement
and the accompanying prospectus electronically. The address of the sales agent is Cowen and Company, LLC, 599 Lexington Avenue, New York,
NY 10022.
LEGAL MATTERS
The validity of the ordinary shares offered and certain other matters
with respect to Swiss law will be passed upon for us by Homburger AG, Zurich, Switzerland. Certain matters with respect to U.S. federal
and New York State law will be passed upon for us by Davis Polk & Wardwell LLP, New York, New York. Cowen and Company, LLC is being
represented in connection with this offering by Cooley LLP, New York, New York with respect to matters of U.S. federal law and Lenz &
Staehelin, Zurich, Switzerland with respect to matters of Swiss law.
EXPERTS
The financial statements incorporated in this
prospectus by reference to the Annual Report on Form 20-F for the year ended December 31, 2022 have been so incorporated in
reliance on the report of PricewaterhouseCoopers SA, an independent registered public accounting firm, given on the authority of
said firm as experts in auditing and accounting. PricewaterhouseCoopers SA is a member of EXPERTsuisse — Swiss Expert Association
for Audit, Tax and Fiduciary.
WHERE YOU CAN FIND MORE INFORMATION
We are subject to the informational requirements of the Exchange Act.
Accordingly, we are required to file reports and other information with the SEC, including Annual Reports on Form 20-F and Reports on
Form 6-K. The SEC maintains an Internet site at www.sec.gov that contains reports, proxy and information statements and other information
we have filed electronically with the SEC. As a foreign private issuer, we are exempt under the Exchange Act from, among other things,
the rules prescribing the furnishing and content of proxy statements, and our executive officers, directors and principal shareholders
are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. In addition, we
are not required under the Exchange Act to file periodic reports and financial statements with the SEC as frequently or as promptly as
U.S. companies whose securities are registered under the Exchange Act.
We have filed with the SEC a “shelf” registration statement
(including amendments and exhibits to the registration statement) on Form F-3 under the Securities Act. This prospectus supplement, which
supplements the accompanying prospectus that is part of the registration statement, does not contain all of the information set forth
in the registration statement and the exhibits and schedules to the registration statement. We have omitted parts of the registration
statement in accordance with the rules and regulations of the SEC. For more detail about us and the securities offered by this prospectus
supplement, you may examine the registration statement on Form F-3 and the exhibits filed with it at the website provided in the previous
paragraph.
We maintain a corporate website at www.sophiagenetics.com. The
reference to our website is an inactive textual reference only, and information contained therein or connected thereto is not incorporated
into this prospectus supplement or the registration statement of which the accompanying prospectus forms a part.
INFORMATION INCORPORATED BY REFERENCE
The rules of the SEC allow us to incorporate by reference information
in this prospectus, which means that we disclose important information to you by referring you to another document filed separately with
the SEC. The information incorporated by reference in this prospectus supplement is considered to be a part of this prospectus supplement.
Any statement made in this prospectus supplement or in a document incorporated or deemed to be incorporated by reference in this prospectus
supplement will be deemed to be modified or superseded for purposes of this prospectus supplement to the extent that a statement contained
in this prospectus supplement or in any other subsequently filed document that is also incorporated or deemed to be incorporated by reference
in this prospectus supplement modifies or supersedes that statement. Any statement so modified or superseded will not be deemed, except
as so modified or superseded, to constitute a part of this prospectus supplement. This prospectus supplement incorporates by reference
the documents listed below:
| · | our Reports on Form 6-K filed with the SEC on March
7, 2023 (only with respect to “2. Compensation of the Board of Directors” and “3. Compensation of the Members
of the Executive Committee” in Exhibit 99.4 thereto), May
9, 2023 (only with respect to Exhibits 99.1 and 99.2 thereto), June
27, 2023 and August 8,
2023 (only with respect to Exhibits 99.1 and 99.2 thereto); and |
All subsequent Annual Reports on Form 20-F, Form 40-F or Form 10-K that
we file with the SEC and all subsequent filings on Forms 10-Q and 8-K filed by us with the SEC pursuant to the Exchange Act (excluding,
in each case, any information or documents deemed to be furnished and not filed with the SEC), after the date hereof and prior to the
completion or termination of this offering, shall be incorporated by reference. We may incorporate by reference any Reports on Form 6-K
that we furnish to the SEC that we specifically identify in such form as being incorporated by reference into this prospectus supplement
after the date of this prospectus supplement and prior to the completion or termination of the offering of securities under this prospectus
supplement.
You can obtain any of the filings incorporated by reference in this
prospectus supplement through us or from the SEC through the SEC’s website at www.sec.gov. Our filings with the SEC, including
our Annual Reports on Form 20-F and Reports on Form 6-K and exhibits incorporated in and amendments to those reports, are also available
free of charge on our website (www.sophiagenetics.com) as soon as reasonably practicable after they are filed with, or furnished
to, the SEC. The reference to our website is an inactive textual reference only, and information contained therein or connected thereto
is not incorporated into this prospectus supplement or the registration statement of which the accompanying prospectus forms a part. We
will provide to each person, including any beneficial owner, to whom this prospectus is delivered, a copy of any or all the reports or
documents incorporated by reference in this prospectus supplement at no cost, upon written or oral request to us at the following address:
Investor Relations
SOPHiA GENETICS SA
c/o SOPHiA GENETICS, Inc.
185 Dartmouth Street Floor 5
Boston, MA 02116
(617) 982-1210
PROSPECTUS
SOPHiA GENETICS SA
$200,000,000
Ordinary Shares
Debt Securities
Warrants
Subscription Rights
Purchase Contracts
Units
We may offer and sell from time to time, in one or more offerings, up
to $200,000,000 of any combination of the following securities: ordinary shares, debt securities, warrants, subscription rights, purchase
contracts and units (collectively, the “securities”). We may offer and sell any combination of the securities described in
this prospectus in different series, at times, in amounts, at prices and on terms to be determined at or prior to the time of each offering.
This prospectus describes the general terms of these securities and the general manner in which these securities will be offered. We will
provide the specific terms of these securities in supplements to this prospectus. The prospectus supplements will also describe the specific
manner in which these securities will be offered and may also supplement, update or amend information contained in this prospectus. You
should read this prospectus and any applicable prospectus supplement before you invest.
The securities covered by this prospectus may be offered through one
or more underwriters, dealers and agents, or directly to purchasers. The applicable prospectus supplement will set forth the names of
the underwriters, dealers or agents, if any, any applicable commissions or discounts payable to them and the specific terms of the plan
of distribution. For general information about the distribution of securities offered, see “Plan of Distribution” beginning
on page 33 of this prospectus.
Our ordinary shares are listed on the Nasdaq Global Select Market (“Nasdaq”)
under the symbol “SOPH.”
Investing in our securities involves a high degree of risk. See the
“Risk Factors” section beginning on page 5 of this prospectus and, if applicable, any risk factors described in any applicable
prospectus supplement and in our Securities and Exchange Commission (“SEC”) filings that are incorporated by reference in
this prospectus.
Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation
to the contrary is a criminal offense.
Prospectus dated August 15, 2022.
TABLE OF CONTENTS
ABOUT THIS PROSPECTUS
This prospectus is a part of a registration statement that we filed
with the SEC using a “shelf” registration process. Under this shelf registration process, we may, from time to time, sell
up to $200,000,000 of any combination of the securities described in this prospectus. This prospectus provides you with a general description
of the securities that may be offered by us. Each time we sell securities, we will provide a prospectus supplement accompanied by this
prospectus. The prospectus supplement will contain specific information about the nature of the persons offering securities and the terms
of the securities being offered at that time. The prospectus supplement may also add, update or change information contained in this prospectus.
Before buying any of the securities that we are offering, you should
carefully read both this prospectus and any prospectus supplement with all of the information incorporated by reference in this prospectus,
as well as the additional information described under the heading “Where You Can Find More Information” and “Information
Incorporated by Reference.” These documents contain important information that you should consider when making your investment decision.
We have filed or incorporated by reference exhibits to the registration statement of which this prospectus forms a part. You should read
the exhibits carefully for provisions that may be important to you.
To the extent there is a conflict between the information contained
in this prospectus, on the one hand, and the information contained in any prospectus supplement or in any document incorporated by reference
in this prospectus, on the other hand, you should rely on the information in this prospectus, provided that if any statement in one of
these documents is inconsistent with a statement in another document having a later date—for example, a prospectus supplement or
a document incorporated by reference in this prospectus—the statement in the document having the later date modifies or supersedes
the earlier statement.
The information contained in this prospectus, any applicable prospectus
supplement or any document incorporated by reference in this prospectus is accurate only as of their respective dates, regardless of the
time of delivery of this prospectus, any applicable prospectus supplement or the documents incorporated by reference in this prospectus
or the sale of any securities. Our business, financial condition, results of operations and prospects may have changed materially since
those dates.
Neither we nor any underwriters, dealers or agents have authorized anyone
to provide you with information that is different from that contained in this prospectus, any amendment or supplement to this prospectus,
or any free writing prospectus we may authorize to be delivered or made available to you. Neither we nor any underwriters, dealers or
agents take responsibility for, or provide assurance as to the reliability of, any other information that others may give you. This prospectus
does not constitute an offer to sell or the solicitation of an offer to buy any securities other than the securities described in this
prospectus or an offer to sell or the solicitation of an offer to buy such securities in any circumstances in which such offer or solicitation
is unlawful.
For investors outside the United States: Neither we nor any underwriters,
dealers or agents have taken any action that would permit the offering or possession or distribution of this prospectus in any jurisdiction
where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession
of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the securities described herein
and the distribution of this prospectus outside the United States.
Unless otherwise indicated or the context otherwise requires, all references
in this prospectus to “SOPHiA GENETICS,” the “Company,” “we,” “our,” “ours,”
“us” or similar terms refer to SOPHiA GENETICS SA and its consolidated subsidiaries.
Trademarks
We own various trademark registrations and applications, and unregistered
trademarks, including for “SOPHiA GENETICS,” “SOPHiA DDM,” “Alamut,” “SOPHiA Trial Match,”
“SOPHiA Insights,” “SOPHiA
CDx,” “SOPHiA Awareness” and our corporate logo. All
other trade names, trademarks and service marks of other companies appearing in this prospectus are the property of their respective owners.
Solely for convenience, the trademarks and trade names in this prospectus may be referred to without the ® and ™ symbols,
but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under
applicable law, their rights thereto. We do not intend to use or display other companies’ trademarks and trade names to imply a
relationship with, or endorsement or sponsorship of us by, any other companies.
Presentation of Financial Information
Our consolidated financial statements are presented in U.S. dollars
and have been prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards
Board (“IFRS”). None of the consolidated financial statements were prepared in accordance with generally accepted accounting
principles in the United States (“U.S. GAAP”). The terms “dollar,” “USD” and “$” refer
to U.S. dollars and the terms “Swiss franc” and “CHF” refer to the legal currency of Switzerland, unless otherwise
indicated. We have made rounding adjustments to some of the figures included in this prospectus. Accordingly, any numerical discrepancies
in any table between totals and sums of the amounts listed are due to rounding.
Market and Industry Data
This prospectus contains industry, market and competitive position data
that are based on general and industry publications, surveys and studies conducted by third parties, some of which may not be publicly
available, and our own internal estimates and research. Third-party publications, surveys and studies generally state that they have obtained
information from sources believed to be reliable, but do not guarantee the accuracy and completeness of such information. While we are
not aware of any misstatements regarding the industry, market and competitive position data presented herein, these data involve a number
of assumptions and limitations and contain projections and estimates of the future performance of the industries in which we operate that
are subject to a high degree of uncertainty.
OUR COMPANY
Overview
We are a healthcare technology company dedicated to establishing the
practice of data-driven medicine as the standard of care and for life sciences research. We are the creator of the SOPHiA DDM™ Platform,
a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities.
Company and Corporate Information
We are a Swiss stock corporation (société anonyme)
incorporated under the laws of Switzerland on March 18, 2011. Our principal executive office is located at Rue du Centre 172, CH-1025
Saint-Sulpice, Switzerland and our telephone number is +41 21 694 10 60. Our agent for service of process in the United States is SOPHiA
GENETICS, Inc., 185 Dartmouth Street, Suite 502, Boston, MA 02116, and its telephone number is (617) 982-1210. Our website is www.sophiagenetics.com.
The reference to our website is an inactive textual reference only, and information contained therein or connected thereto is not incorporated
into this prospectus or the registration statement of which it forms a part.
Implications of Being an Emerging Growth Company and Foreign Private
Issuer
We qualify as an “emerging growth company” as defined in
the Jumpstart our Business Startups Act of 2012 (the “JOBS Act”). As an emerging growth company, we may take advantage of
specified reduced reporting and other burdens that are otherwise applicable generally to public companies. These provisions include:
| · | an exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting pursuant
to Section 404 of the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”); and |
| · | to the extent that we no longer qualify as a foreign private issuer, (i) reduced disclosure obligations regarding executive compensation
in our periodic reports and proxy statements and (ii) exemptions from the requirements of holding a non-binding advisory vote on
executive compensation, including golden parachute compensation. |
We may take advantage of these provisions for up to five years or such
earlier time that we are no longer an emerging growth company. We will remain an emerging growth company until the earliest of (i) the
last day of the fiscal year in which we have total annual gross revenues of $1.07 billion or more; (ii) December 31, 2026; (iii) the
date on which we have issued more than $1.0 billion in non-convertible debt during the previous three years; and (iv) the date
on which we are deemed to be a large accelerated filer under the rules of the SEC, which means the market value of our ordinary shares
that are held by non-affiliates equals or exceeds $700.0 million as of the prior June 30. We may choose to take advantage of some
but not all of these reduced burdens. For example, Section 107 of the JOBS Act also provides that an emerging growth company can take
advantage of an extended transition period for complying with new or revised accounting standards applicable to public companies. This
provision allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise
apply to private companies. This transition period is only applicable under U.S. GAAP. As a result, we will adopt new or revised accounting
standards on the relevant dates on which adoption of such standards is required or permitted by the International Accounting Standards
Board.
We are also considered a “foreign private issuer.” Accordingly,
we report under the Exchange Act of 1934, as amended (the “Exchange Act”), as a non-U.S. company with foreign private issuer
status. This means that, even after we no longer qualify as an emerging growth company, as long as we qualify as a foreign private issuer
under the Exchange Act, we will be exempt from certain provisions of the Exchange Act that are applicable to U.S. domestic public companies,
including:
| · | the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered
under the Exchange Act; |
| · | the sections of the Exchange Act requiring insiders to file public reports of their stock ownership and trading activities and liability
for insiders who profit from trades made in a short period of time; and |
| · | the rules under the Exchange Act requiring the filing with the SEC of quarterly reports on Form 10-Q containing unaudited financial
and other specified information, or current reports on Form 8-K, upon the occurrence of specified significant events. |
We may take advantage of these exemptions until such time as we are
no longer a foreign private issuer. We would cease to be a foreign private issuer at such time as more than 50% of our outstanding voting
securities are held by U.S. residents and any of the following three circumstances applies: (i) the majority of our executive officers
or directors are U.S. citizens or residents, (ii) more than 50% of our assets are located in the United States or (iii) our
business is administered principally in the United States.
In this prospectus and in the documents incorporated by reference in
this prospectus, we have taken advantage of certain of the reduced reporting requirements as a result of being an emerging growth company
and a foreign private issuer. Accordingly, the information contained in this prospectus and in the documents incorporated by reference
in this prospectus may be different than the information you receive from other public companies in which you hold equity securities.
RISK FACTORS
Investing in our securities involves risk. Before making a decision
to invest in our securities, you should carefully consider the risks described under “Risk Factors” in the applicable prospectus
supplement and in our then-most recent Annual Report on Form 20-F, and any updates to those risk factors in our reports on Form 6-K incorporated
by reference in this prospectus, together with all of the other information appearing or incorporated by reference in this prospectus
and any applicable prospectus supplement, in light of your particular investment objectives and financial circumstances. Although we discuss
key risks in our discussion of risk factors, new risks may emerge in the future, which may prove to be significant. We cannot predict
future risks or estimate the extent to which they may affect our business, results of operations, financial condition and prospects.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING
STATEMENTS
This prospectus and the documents incorporated by reference in this
prospectus contain statements that constitute forward-looking statements within the meaning of Section 21E of the Exchange Act and Section
27A of the Securities Act of 1933, as amended (the “Securities Act”). All statements other than statements of historical facts,
including statements regarding our future results of operations and financial position, business strategy, technology, collaborations
and partnerships, as well as plans and objectives of management for future operations are forward-looking statements. Many of the forward-looking
statements contained in this prospectus can be identified by the use of forward-looking words such as “anticipate,” “believe,”
“could,” “expect,” “should,” “plan,” “intend,” “estimate,” “will”
and “potential,” among others.
Forward-looking statements are based on our management’s beliefs
and assumptions and on information available to our management at the time such statements are made. Such statements are subject to risks
and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various
factors, including, but not limited to, those identified under the “Risk Factors” section of this prospectus and in the documents
incorporated by reference in this prospectus. Forward-looking statements speak only as of the date on which they were made. Because forward-looking
statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond
our control, you should not rely on these forward-looking statements as predictions of future events. Moreover, we operate in an evolving
environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk
factors and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements,
whether as a result of any new information, future events, changed circumstances or otherwise. You should read this prospectus, the documents
incorporated by reference in this prospectus and the documents that we have filed as exhibits to the registration statement of which this
prospectus is a part completely and with the understanding that our actual future results may be materially different from what we expect.
In addition, statements that “we believe” and similar statements
reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of
such statements, and while we believe such information forms a reasonable basis for such statements, such information may be limited or
incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially
available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.
USE OF PROCEEDS
Unless otherwise indicated in a prospectus supplement, the principal
purpose of an offering would be to increase our capitalization and financial flexibility and the net proceeds from our sale of the securities
will be used for general corporate purposes and other business opportunities.
DIVIDEND POLICY
We have never declared or paid cash dividends on our share capital.
We intend to retain all available funds and any future earnings, if any, to fund the development and expansion of our business, and we
do not anticipate paying any cash dividends in the foreseeable future. Any future determination related to dividend policy will be made
at the discretion of our board of directors and will depend upon, among other factors, our results of operations, financial condition,
capital requirements, contractual restrictions, business prospects and other factors our board of directors may deem relevant.
Under Swiss law, any dividend must be approved by our shareholders.
In addition, our auditors must confirm that the dividend proposal of our board of directors to the shareholders conforms to Swiss statutory
law and our articles of association. A Swiss corporation may pay dividends only if it has sufficient distributable profits from the previous
business year (bénéfice de l’exercice) or brought forward from previous business years (report des bénéfices)
or if it has distributable reserves (réserves à libre disposition), each as evidenced by its audited stand-alone
statutory balance sheet prepared pursuant to Swiss law and after allocations to reserves required by Swiss law and its articles of association
have been deducted. Distributable reserves are generally booked either as free reserves (réserves libres) or as reserves
from capital contributions (apports de capital). Distributions out of share capital, which is the aggregate par value of a corporation’s
issued shares, may be made only by way of a share capital reduction. See “Description of Share Capital and Articles of Association.”
DESCRIPTION OF SHARE CAPITAL AND ARTICLES OF
ASSOCIATION
Share Capital
As of June 30, 2022, our share capital as registered with the commercial
register of the Canton of Vaud, Switzerland (the “Commercial Register”) amounted to CHF 3,319,908.20 and was divided into
66,398,164 ordinary shares, with a par value of CHF 0.05 per share.
Changes in Our Share Capital During the Last Three Fiscal Years
In this section, share amounts are presented as of the date of the relevant
transaction. Since January 1, 2019, our share capital has changed as follows:
| · | On May 29, 2020, our share capital as registered with the Commercial Register was updated to reflect the issuance of 39,975 ordinary
shares out of conditional share capital; |
| · | On June 25, 2020, our share capital as registered with the Commercial Register on June 25, 2020, was increased by issuing 283,224
Series F preferred shares; |
| · | On September 23, 2020, our share capital as registered with the Commercial Register on September 29, 2020 was increased by issuing
182,623 Series F preferred shares; |
| · | On June 25, 2021, our share capital as registered with the Commercial Register was updated to reflect the issuance of 74,265 ordinary
shares out of conditional share capital; |
| · | In the one-to-twenty share split of all issued shares effected on June 30, 2021, each of our issued shares was split into 20 shares
of the same class with a par value of CHF 0.05 per share; |
| · | On July 26, 2021, our entire share capital as registered with the Commercial Register on July 27, 2021 was converted into ordinary
shares; |
| · | On July 26, 2021, our share capital as registered with the Commercial Register on July 27, 2021 was increased by issuing 14,111,111
ordinary shares; |
| · | On August 24, 2021, our share capital as registered with the Commercial Register on August 25, 2021 was increased by issuing 519,493
ordinary shares; and |
| · | On April 26, 2022, our share capital as registered with the Commercial Register on April 29, 2022 was updated to reflect the issuance
of 2,540,560 ordinary shares out of conditional share capital. |
Articles of Association
Ordinary Capital Increase, Authorized and Conditional Share Capital
Under Swiss law, we may increase our share capital (capital-actions)
with a resolution of the general meeting of shareholders (ordinary capital increase) that must be carried out by the board of directors
within three months of the respective general meeting in order to become effective. Under our articles of association and Swiss law, in
the case of subscription and increase against payment of contributions in cash, a resolution passed by an absolute majority of the shares
represented at the general meeting of shareholders is required. In the case of subscription and increase against contributions in kind
or to fund acquisitions in kind, when shareholders’ statutory pre-emptive subscription rights or advance subscription rights are
limited or withdrawn or where transformation of freely disposable equity into share capital is involved, a resolution passed by two-thirds
of the shares represented at a general meeting of shareholders and the absolute majority of the par value of the shares represented is
required.
Furthermore, under the Swiss Code of Obligations (Code des obligations)
(the “Code of Obligations”), our shareholders, by a resolution passed by two-thirds of the shares represented at a general
meeting of shareholders and the absolute majority of the par value of the shares represented, may empower our
board of directors to issue shares of a specific aggregate par value
up to a maximum of 50% of the share capital in the form of:
| · | conditional share capital (capital-actions conditionnel) for the purpose of issuing shares in connection with, among other
things, (i) option and conversion rights granted in connection with warrants and convertible bonds of the Company or one of our subsidiaries
or (ii) grants of rights to employees, members of our board of directors or consultants or to our subsidiaries or other persons providing
services to the Company or a subsidiary to subscribe for new shares (conversion or option rights); or |
| · | authorized share capital (capital-actions autorisé) to be utilized by the board of directors within a period determined
by the shareholders but not exceeding two years from the date of the shareholder approval. |
Pre-Emptive and Advance Subscription Rights
Pursuant to the Code of Obligations, shareholders have pre-emptive subscription
rights (droits de souscription préférentiels) to subscribe for new issuances of shares. With respect to conditional
capital in connection with the issuance of conversion rights, convertible bonds or similar debt instruments, shareholders have advance
subscription rights (droit de souscrire préalablement) for the subscription of such conversion rights, convertible bonds
or similar debt instruments.
A resolution passed at a general meeting of shareholders by two-thirds
of the shares represented and the absolute majority of the par value of the shares represented may authorize our board of directors to
withdraw or limit pre-emptive subscription rights or advance subscription rights in certain circumstances.
If pre-emptive subscription rights are granted, but not exercised, the
board of directors may allocate the unexercised pre-emptive subscription rights at its discretion.
Our Authorized Share Capital
Under our articles of association, our board of directors is authorized
at any time, including to prevent takeovers and changes in control, until June 14, 2024 at the latest to increase our nominal share capital
by a maximum aggregate amount of CHF 1,659,954.10 through the issuance of not more than 33,199,082 ordinary shares, which would have to
be fully paid-in, each with a par value of CHF 0.05 per share.
Increases in partial amounts are permitted. The board of directors has
the power to determine the date of issue, the conditions for the exercise of pre-emptive subscription rights, the type of contributions,
the issue price and the date on which the dividend entitlement starts.
With respect to our authorized share capital, the board of directors
is authorized by our articles of association to withdraw or to limit the pre-emptive subscription rights of shareholders, and to allocate
them to third parties or to us, in the event that the newly issued shares are issued under the following circumstances:
| · | if the issue price of the new registered shares is determined by reference to the market price; |
| · | for raising of capital (including private placements) in a fast and flexible manner, which would not be possible, or might only be
possible with great difficulty or delays or at significantly less favorable conditions, without the exclusion of the statutory pre-emptive
subscription rights of the existing shareholders; |
| · | for the acquisition of an enterprise, parts of an enterprise or participations, for the acquisition of products, intellectual property
or licenses by or for investment projects of the Company or any of its group companies, or for the financing or refinancing of any of
such transactions through a placement of shares; |
| · | for purposes of broadening the shareholder constituency of the Company in certain geographic, financial or investor markets, for purposes
of the participation of strategic partners, or in connection with the listing of new shares on domestic or foreign stock exchanges; |
| · | for purposes of granting an over-allotment option or an option to purchase additional shares in a placement or sale of shares to the
respective initial purchaser(s) or underwriter(s); |
| · | for the participation of members of the board of directors or equivalent corporate body, members of the executive committee, employees,
contractors, consultants or other persons performing services for the benefit of the Company or any of its group companies; |
| · | following a shareholder or a group of shareholders acting in concert having accumulated shareholdings in excess of 15% of our share
capital registered in the Commercial Register without having submitted to all other shareholders a takeover offer recommended by the board
of directors; |
| · | for the defense of an actual, threatened or potential takeover bid, that the board of directors, upon consultation with an independent
financial adviser retained by it, has not recommended or will not recommend to the shareholders for acceptance on the basis that the board
of directors has not found the takeover bid to be financially fair to the shareholders or not to be in the Company’s interest; or |
| · | for other valid grounds in the sense of Article 652b para. 2 of the Code of Obligations. |
This authorization is exclusively linked to the particular available
authorized share capital set out in the respective article. If the period to increase our share capital out of authorized share capital
lapses without having been used by the board of directors, the authorization to withdraw or to limit the pre-emptive subscription rights
lapses simultaneously with such capital.
Our Conditional Share Capital
Conditional Share Capital for Financing, Acquisitions and Other Purposes
Our nominal share capital may be increased, including to prevent takeovers
and changes in control, by a maximum aggregate amount of CHF 1,079,954.10 through the issuance of not more than 21,599,082 ordinary
shares, which would have to be fully paid-in, each with a par value of CHF 0.05 per share, by the exercise of option and conversion rights
granted in connection with warrants, convertible bonds or similar instruments of the Company or one of our subsidiaries. Shareholders
will not have pre-emptive subscription rights in such circumstances, but will have advance subscription rights to subscribe for such warrants,
convertible bonds or similar instruments. The holders of warrants, convertible bonds or similar instruments are entitled to the new shares
upon the occurrence of the applicable conversion feature.
When issuing convertible bonds, warrants or similar instruments, the
board of directors is authorized to withdraw or to limit the advance subscription right of shareholders:
| · | for the purpose of financing or refinancing, or the payment for, the acquisition of enterprises, parts of enterprises, participations,
intellectual property rights, licenses or investments; |
| · | if the issuance occurs in domestic or international capital markets, including private placements; |
| · | following a shareholder or a group of shareholders acting in concert having accumulated shareholdings in excess of 15% of the share
capital registered in the Commercial Register without having submitted to all other shareholders a takeover offer recommended by the board
of directors; or |
| · | for the defense of an actual, threatened or potential takeover bid that the board of directors, upon consultation with an independent
financial adviser retained by it, has not recommended or will not |
recommend to the shareholders to accept on the basis that
the board of directors has not found the takeover bid to be financially fair to the shareholders or not to be in the Company’s interest.
To the extent that the advance subscription rights are withdrawn or
limited, (i) the convertible bonds, warrants or similar instruments are to be issued at market conditions; (ii) the term to
exercise the convertible bonds, warrants or similar instruments may not exceed ten years from the date of issue of the respective instrument
and (iii) the conversion, exchange or exercise price of the convertible bonds, warrants or similar instruments has to be set with
reference to or be subject to change based upon the valuation of the Company’s equity or market conditions.
Conditional Share Capital for Employee Participation
Our nominal share capital may, to the exclusion of the pre-emptive subscription
rights and advance subscription rights of shareholders, be increased by a maximum aggregate amount of CHF 580,000 through the (direct
or indirect) issuance of not more than 11,600,000 ordinary shares, which would have to be fully paid-in, each with a par value of CHF
0.05 per share, by the exercise of options, other rights to receive shares or conversion rights that have been granted to employees, members
of the board of directors or equivalent corporate body, contractors or consultants of the Company or of one of our subsidiaries or other
persons providing services to the Company or to a subsidiary.
Uncertificated Securities
Our shares are in the form of uncertificated securities (droits-valeurs,
within the meaning of Article 973c of the Code of Obligations). In accordance with Article 973c of the Code of Obligations, we will maintain
a non-public register of uncertificated securities (registre des droits-valeurs). We may at any time convert our shares from one
form into another form (including uncertificated securities into registered uncertificated securities (droits-valeurs inscrits,
within the meaning of Article 973d of the Code of Obligations)), share certificates (or global certificates), one kind of certificate
into another, or share certificates, global certificates or registered uncertificated securities into uncertificated securities. Following
entry in the share register, a shareholder may at any time request from us a written confirmation in respect of his or her shares. Shareholders
are not entitled, however, to request the conversion and/or printing and delivery of share certificates. We may print and deliver certificates
for shares at any time.
General Meeting of Shareholders
Ordinary/Extraordinary Meetings, Powers
The general meeting of shareholders is our supreme corporate body. Under
Swiss law, an annual general meeting of shareholders must be held annually within six months after the end of a corporation’s financial
year. In our case, this generally means on or before June 30. In addition, extraordinary general meetings of shareholders may be held.
The following powers are vested exclusively in the general meeting of
shareholders:
| · | adopting and amending the articles of association, including the change of a company’s purpose or domicile; |
| · | electing the members of the board of directors, the chairman of the board of directors, the members of the compensation committee,
the auditors and the independent proxy; |
| · | approving the management report, the annual statutory and consolidated financial statements and deciding on the allocation of profits
as shown on the balance sheet, in particular with regard to dividends; |
| · | approving the aggregate amount of compensation of members of the board of directors and the executive committee; |
| · | discharging the members of the board of directors and the executive committee from liability with respect to their conduct of business; |
| · | dissolving a company with or without liquidation; and |
| · | deciding matters reserved to the general meeting of shareholders by law or the articles of association or submitted to it by the board
of directors. |
An extraordinary general meeting of shareholders may be called by a
resolution of the board of directors or the general meeting of shareholders or, under certain circumstances, by a company’s auditor,
liquidator or the representatives of bondholders, if any. In addition, the board of directors is required to convene an extraordinary
general meeting of shareholders if shareholders representing at least 10% of our share capital request such general meeting of shareholders
in writing. Such request must set forth the items to be discussed and the proposals to be acted upon. The board of directors must convene
an extraordinary general meeting of shareholders and propose financial restructuring measures if, based on our stand-alone annual statutory
balance sheet, half of our share capital and statutory reserves are not covered by our assets.
Voting and Quorum Requirements
Shareholder resolutions and elections (including elections of members
of the board of directors) require the affirmative vote of the absolute majority of shares represented at the general meeting of shareholders,
unless otherwise stipulated by law or our articles of association.
Under Swiss law and our articles of association, a resolution of the
general meeting of the shareholders passed by two-thirds of the shares represented at the meeting and the absolute majority of the par
value of the shares represented is required for:
| · | amending the Company’s corporate purpose; |
| · | creating shares with privileged voting rights; |
| · | cancelling or amending the transfer restrictions of shares; |
| · | creating authorized or conditional share capital; |
| · | increasing share capital out of equity, against contributions in-kind or for the purpose of acquiring specific assets and granting
specific benefits; |
| · | limiting or withdrawing shareholders’ pre-emptive subscription rights; |
| · | changing a company’s domicile; |
| · | amending or repealing certain of the authorizations of the board of directors to place shares with affiliates or third parties without
existing shareholders having statutory pre-emptive rights, or amending or repealing the voting and recording restrictions, the provision
setting a maximum board size or the indemnification provision for the board of directors and the executive committee set forth in our
articles of association; |
| · | converting registered shares into bearer shares; |
| · | removing the chairman or any member of the board of directors before the end of his or her term of office; and |
| · | dissolving or liquidating the Company. |
The same voting requirements apply to resolutions regarding transactions
among corporations based on Switzerland’s Federal Act on Mergers, Demergers, Transformations and the Transfer of Assets of 2003,
as amended (the “Swiss Merger Act”). See “—Articles of Association—Compulsory Acquisitions; Appraisal Rights.”
In accordance with Swiss law and generally accepted business practices,
our articles of association do not provide quorum requirements generally applicable to general meetings of shareholders. To this extent,
our practice varies from Nasdaq listing standards, which require an issuer to provide in its bylaws for a generally applicable quorum
and that such quorum may not be less than one-third of the outstanding voting shares.
Notice
General meetings of shareholders must be convened by the board of directors
at least 20 days before the date of the meeting. The general meeting of shareholders is convened by way of a notice appearing in our official
publication medium, currently the Swiss Official Gazette of Commerce. Registered shareholders may also be informed by ordinary mail or
e-mail. The notice of a general meeting of shareholders must state the items on the agenda, the motions to the shareholders and, in case
of elections, the names of the nominated candidates. A resolution on a matter which is not on the agenda may not be passed at a general
meeting of shareholders, except for motions to convene an extraordinary general meeting of shareholders or to initiate a special investigation,
on which the general meeting of shareholders may vote at any time. No previous notification is required for motions concerning items included
in the agenda or for debates that do not result in a vote.
All of the owners or representatives of our shares may, if no objection
is raised, hold a general meeting of shareholders without complying with the formal requirements for convening general meetings of shareholders
(a universal meeting). This universal meeting of shareholders may discuss and pass binding resolutions on all matters within the
purview of the general meeting of shareholders, provided that the owners or representatives of all the shares are present at the meeting.
Agenda Requests
Pursuant to Swiss law and our articles of association, one or more shareholders
whose combined shareholdings represent the lesser of (i) one tenth of our share capital and (ii) an aggregate par value of at
least CHF 1,000,000 may request that an item be included in the agenda for a general meeting of shareholders. To be timely, the shareholder’s
request must be received by us generally at least 45 calendar days in advance of the meeting. The request must be made in writing and
contain, for each of the agenda items, the following information:
| · | a brief description of the business desired to be brought before the general meeting of shareholders and the reasons for conducting
such business at the general meeting of shareholders; |
| · | the motions regarding the agenda item; |
| · | the name and address, as they appear in the share register, of the shareholder proposing such business; |
| · | the number of shares which are beneficially owned by such shareholder (including documentary support of such beneficial ownership); |
| · | the dates upon which the shareholder acquired such shares; |
| · | any material interest of the proposing shareholder in the proposed business; |
| · | a statement in support of the matter; and |
| · | all other information required under the applicable laws and stock exchange rules. |
In addition, if the shareholder intends to solicit proxies from the
shareholders of a company, such shareholder shall notify the company of this intent in accordance with SEC Rule 14a-4 and/or Rule 14a-8.
Our business report, the compensation report and the auditor’s
report must be made available for inspection by the shareholders at our registered office no later than 20 days prior to the general meeting
of shareholders. Shareholders of record may be notified of this in writing.
Voting Rights
Each of our ordinary shares entitles a holder to one vote. The ordinary
shares are not divisible. The right to vote and the other rights of share ownership may only be exercised by shareholders (including any
nominees) or usufructuaries who are entered in the share register at a cut-off date determined by the board of directors. Those entitled
to vote in the general meeting of shareholders may be represented by the independent proxy holder (annually elected by the general meeting
of shareholders), by its legal representative or by another registered shareholder with written authorization to act as proxy. The chairman
has the power to decide whether to recognize a power of attorney.
Our articles of association contain provisions that prevent investors
from acquiring and exercising voting rights exceeding 15% of our issued share capital. Specifically, if an individual or legal entity
acquires ordinary shares and, as a result, directly or indirectly, has voting rights with respect to more than 15% of the registered share
capital recorded in the Commercial Register, the registered shares exceeding the limit of 15% shall be entered in the share register as
shares without voting rights (limitation à l’inscription). This restriction applies equally to parties acting in concert
and to shares held or acquired via a nominee, including via Cede & Co., New York (or any successor), as the nominee of The Depository
Trust Company (“DTC”), New York, acting in its capacity as clearing nominee. Specifically, if shares are being held by a nominee
for third-party beneficiaries, which control (alone or together with third parties) voting rights with respect to more than 15% of the
share capital recorded in the Commercial Register, our articles of association provide that the board of directors may cancel the registration
of the shares with voting rights held by such nominee in excess of the limit of 15%. Our articles of association also contain provisions
that allow the board of directors to make the registration with voting rights of shares held by a nominee subject to conditions, limitations
and reporting requirements or to impose or adjust such conditions, limitations and requirements once registered.
Furthermore, our articles of association contain provisions that prevent
shareholders and proxies from exercising voting rights attached to their own or represented ordinary shares that would collectively exceed
15% the share capital recorded in the commercial register. This restriction applies equally to parties acting in concert and to shares
held or acquired via a nominee, as described above, but not to the independent proxy acting as proxy on behalf of shareholders.
Notwithstanding the above, any shareholders holding more than 15% prior
to the filing and effectiveness of our amended and restated articles of association will remain registered with voting rights for such
shares and will be able to exercise their voting rights in full. Furthermore, the board of directors may in special cases approve exceptions
to these restrictions.
Dividends and Other Distributions
Our board of directors may propose to shareholders that a dividend or
other distribution be paid but cannot itself authorize the distribution. Dividend payments require a resolution passed by an absolute
majority of the shares represented at a general meeting of shareholders. In addition, our auditors must confirm that the dividend proposal
of our board of directors conforms to Swiss statutory law and our articles of association.
Under Swiss law, we may pay dividends only if we have sufficient distributable
profits from the previous business year (bénéfice de l’exercice), or brought forward from the previous business
years (report des bénéfices) or if we have distributable reserves (réserves à libre disposition),
each as evidenced by the
Company’s audited stand-alone statutory balance sheet prepared
pursuant to Swiss law and after allocations to reserves required by Swiss law and by the articles of association have been deducted. We
are not permitted to pay interim dividends out of profit of the current business year.
Distributable reserves are generally booked either as “free reserves”
(réserves libres) or as “reserve from capital contributions” (apports de capital). Under the Code
of Obligations, if our general reserves (réserve générale) amount to less than 20% of our share capital
recorded in the Commercial Register (i.e., 20% of the aggregate par value of our issued capital), then at least 5% of our annual profit
must be retained as general reserves. In addition, if our general reserves amount to less than 50% of our share capital recorded in the
Commercial Register, 10% of the amounts distributed beyond payment of a dividend of 5% must be retained as general reserves. The Code
of Obligations permits us to accrue additional general reserves. Further, a purchase of our own shares (whether by us or a subsidiary)
reduces the distributable reserves in an amount corresponding to the purchase price of such own shares. Finally, the Code of Obligations
under certain circumstances requires the creation of revaluation reserves, which are not distributable.
Distributions out of issued share capital (i.e., the aggregate par value
of our issued shares) are not allowed and may be made only by way of a share capital reduction. Such a capital reduction requires a resolution
passed by an absolute majority of the shares represented at a general meeting of shareholders. The resolution of the shareholders must
be recorded in a public deed and a special audit report must confirm that claims of our creditors remain fully covered despite the reduction
in our share capital recorded in the Commercial Register. Our share capital may be reduced below CHF 100,000 only if and to the extent
that at the same time the statutory minimum share capital of CHF 100,000 is reestablished by sufficient new, fully paid-up capital. Upon
approval by the general meeting of shareholders of the capital reduction, the board of directors must give public notice of the capital
reduction resolution in the Swiss Official Gazette of Commerce three times and notify creditors that they may request, within two months
of the third publication, satisfaction of or security for their claims. The reduction of our share capital may be implemented only after
expiration of this time limit.
Our board of directors determines the date on which the dividend entitlement
starts. Dividends are usually due and payable shortly after the shareholders have passed the resolution approving the payment, but shareholders
may also resolve at the annual general meeting of shareholders to pay dividends in quarterly or other installments.
Transfer of Shares
Shares in uncertificated form (droits-valeurs) may only be transferred
by way of assignment. Shares or the beneficial interest in shares, as applicable, credited in a securities account may only be transferred
when a credit of the relevant intermediated securities to the acquirer’s securities account is made in accordance with applicable
rules. Our articles of association provide that in the case of securities held with an intermediary such as a registrar, transfer agent,
trust corporation, bank or similar entity, any transfer, grant of a security interest or usufructuary right in such intermediated securities
and the appurtenant rights associated therewith requires the cooperation of the intermediary in order for such transfer, grant of a security
interest or usufructuary right to be valid against us.
Voting rights may be exercised only after a shareholder has been entered
in the share register (registre des actions) with his or her name and address (in the case of legal entities, the registered office)
as a shareholder with voting rights. For a discussion of the restrictions applicable to the control and exercise of voting rights, see
“—Articles of Association—Voting Rights.”
Inspection of Books and Records
Under the Code of Obligations, a shareholder has a right to inspect
the share register with respect to his or her own shares and otherwise to the extent necessary to exercise his or her shareholder rights.
No other person has a right to inspect the share register. Our books and correspondence may be inspected with the express authorization
of the general meeting of shareholders or by resolution of the board of
directors and subject to the safeguarding of our business secrets and
other legitimate interests. See “—Comparison of Swiss Law and Delaware Law—Inspection of books and records.”
Special Investigation
If the shareholders’ inspection rights as outlined above prove
to be insufficient in the judgment of the shareholder, any shareholder may propose to the general meeting of shareholders that specific
facts be examined by a special examiner in a special investigation. If the general meeting of shareholders approves the proposal, we or
any shareholder may, within 30 calendar days after the general meeting of shareholders, request a court at our registered office (currently
Saint-Sulpice, Canton of Vaud, Switzerland) to appoint a special examiner. If the general meeting of shareholders rejects the request,
one or more shareholders representing at least 10% of our share capital or holders of shares in an aggregate par value of at least CHF
2,000,000 may request that the court appoint a special examiner. The court will issue such an order if the petitioners can demonstrate
that the board of directors, any member of the board of directors or our executive committee infringed the law or our articles of association
and thereby caused damages to the Company or the shareholders. The costs of the investigation would generally be allocated to us and only
in exceptional cases to the petitioners.
Compulsory Acquisitions; Appraisal Rights
Business combinations and other transactions that are governed by the
Swiss Merger Act (i.e., mergers, demergers, transformations and certain asset transfers) are binding on all shareholders. A statutory
merger or demerger requires approval of two-thirds of the shares represented at a general meeting of shareholders and the absolute majority
of the par value of the shares represented.
If a transaction under the Swiss Merger Act receives all of the necessary
consents, all shareholders are compelled to participate in such transaction.
Swiss corporations may be acquired by an acquirer through the direct
acquisition of the shares of the Swiss corporation. The Swiss Merger Act provides for the possibility of a so-called “cash-out”
or “squeeze-out” merger with the approval of holders of 90% of the issued shares. In these limited circumstances, minority
shareholders of the corporation being acquired may be compensated in a form other than through shares of the acquiring corporation (for
instance, through cash or securities of a parent corporation of the acquiring corporation or of another corporation). For business combinations
effected in the form of a statutory merger or demerger and subject to Swiss law, the Swiss Merger Act provides that if equity rights have
not been adequately preserved or compensation payments in the transaction are unreasonable, a shareholder may request the competent court
to determine a reasonable amount of compensation.
In addition, under Swiss law, the sale of “all or substantially
all of our assets” by us may require the approval of two-thirds of the number of shares represented at a general meeting of shareholders
and the absolute majority of the par value of the shares represented. Whether a shareholder resolution is required depends on the particular
transaction, including whether the following test is satisfied:
| · | a core part of our business is sold, without which it is economically impracticable or unreasonable to continue to operate the remaining
business; |
| · | our assets, after the divestment, are not invested in accordance with our corporate purpose as set forth in the articles of association;
and |
| · | the proceeds of the divestment are not earmarked for reinvestment in accordance with our corporate purpose but, instead, are intended
for distribution to our shareholders or for financial investments unrelated to our corporate purpose. |
A shareholder of a Swiss corporation participating in certain major
corporate transactions may, under certain circumstances, be entitled to appraisal rights. As a result, such shareholder may, in addition
to the consideration (be it in shares or in cash) receive an additional amount to ensure that the shareholder
receives the fair value of the shares held by the shareholder. Following
a statutory merger or demerger, pursuant to the Swiss Merger Act, shareholders can file an appraisal action against the surviving company.
If the consideration is deemed inadequate, the court will determine an adequate compensation payment.
Board of Directors
Our articles of association provide that the board of directors shall
consist of at least three and not more than eight members.
The members of the board of directors and the chairman are elected annually
by the general meeting of shareholders for a period until the completion of the subsequent annual general meeting of shareholders and
are eligible for re-election. Each member of the board of directors must be elected individually.
Powers
The board of directors has the following non-delegable and inalienable
powers and duties:
| · | the ultimate direction of the business of the Company and issuing of the relevant directives; |
| · | laying down the organization of the Company; |
| · | formulating accounting procedures, financial controls and financial planning; |
| · | nominating and removing persons entrusted with the management and representation of the Company and regulating the power to sign for
the Company; |
| · | the ultimate supervision of those persons entrusted with management of the Company, with particular regard to adherence to law, our
articles of association and regulations and directives of the Company; |
| · | issuing the business report and the compensation report, and preparing for the general meeting of shareholders and carrying out its
resolutions; and |
| · | informing the court in case of over-indebtedness. |
The board of directors may, while retaining such non-delegable and inalienable
powers and duties, delegate some of its powers, in particular direct management, to a single or to several of its members, committees
or to third parties (such as executive officers) who need be neither members of the board of directors nor shareholders. Pursuant to Swiss
law and our articles of association, details of the delegation and other procedural rules such as quorum requirements have been set in
the organizational rules established by the board of directors.
Indemnification of Executive Officers and Directors
Subject to Swiss law, our articles of association provide for indemnification
of the existing and former members of the board of directors and the executive committee and their heirs, executors and administrators
against liabilities arising in connection with the performance of their duties in such capacity, and permit us to advance the expenses
of defending any act, suit or proceeding to our directors and executive officers to the extent not included in insurance coverage or advanced
by third parties.
In addition, under general principles of Swiss employment law, an employer
may be required to indemnify an employee against losses and expenses incurred by such employee in the proper execution of his or her duties
under the employment agreement with the employer. See “—Comparison of Swiss Law and Delaware Law—Indemnification of
directors and executive officers and limitation of liability.”
Conflict of Interest, Management Transactions
Swiss law does not have a general provision regarding conflicts of interest.
However, the Code of Obligations contains a provision that requires our directors and executive officers to safeguard the Company’s
interests and imposes a duty of loyalty and duty of care on our directors and executive officers. This rule is generally understood to
disqualify directors and executive officers from participation in decisions that directly affect them. Our directors and executive officers
are personally liable to us for breaches of these obligations. In addition, Swiss law contains provisions under which directors and all
persons engaged in the Company’s management are liable to the Company, each shareholder and the Company’s creditors for damages
caused by an intentional or negligent violation of their duties. Furthermore, Swiss law contains a provision under which payments made
to any of the Company’s shareholders or directors or any person related to any such shareholder or director, other than payments
made at arm’s length, must be repaid to the Company if such shareholder or director acted in bad faith.
Our board of directors has adopted a Code of Ethics and other policies
that cover a broad range of matters, including the handling of conflicts of interest.
Principles of the Compensation of the Board of Directors and
the Executive Committee
Pursuant to Swiss law, our shareholders must annually approve the aggregate
amount of compensation of the board of directors and the persons whom the board of directors has, fully or partially, entrusted with the
management (which we refer to as our “executive committee”) of the Company. All of our executive officers named in “Management”
are deemed to be members of our executive committee.
The board of directors must issue, on an annual basis, a written compensation
report that must be reviewed by our auditors. The compensation report must disclose all compensation granted by the Company, directly
or indirectly, to current members of the board of directors and the executive committee and, to the extent related to their former role
within the Company or not on customary market terms, to former members of the board of directors and former executive officers.
The disclosure concerning compensation, loans and other forms of indebtedness
must include the aggregate amount for the board of directors and the executive committee, respectively, as well as the particular amount
for each member of the board of directors and for the highest-paid executive officer, specifying the name and function of each of these
persons.
We are prohibited from granting certain forms of compensation to members
of our board of directors and executive committee, such as:
| · | severance payments (compensation due until the termination of a contractual relationship does not qualify as severance payment); |
| · | incentive fees for the acquisition or transfer of companies, or parts thereof, by the Company or by companies being directly or indirectly
controlled by us; |
| · | loans, other forms of indebtedness, pension benefits not based on occupational pension schemes and performance-based compensation
not provided for in the articles of association; and |
| · | equity-based compensation not provided for in the articles of association. |
Compensation to members of the board of directors and the executive
committee for activities in entities that are directly or indirectly controlled by the Company is prohibited if (i) the compensation
would be
prohibited if it were paid directly by the Company, (ii) the articles
of association do not provide for it, or (iii) the compensation has not been approved by the general meeting of shareholders.
The general meeting of shareholders will annually vote on the proposals
of the board of directors with respect to:
| · | the maximum aggregate amount of compensation of the board of directors for the term of office until the next annual general meeting
of shareholders; |
| · | the maximum aggregate amount of fixed compensation of the executive committee for the following financial year; and |
| · | the maximum aggregate amount of variable compensation of the executive committee for the current financial year. |
The board of directors may submit for approval at the general meeting
of shareholders deviating or additional proposals relating to the same or different periods.
If, at the general meeting of shareholders, the shareholders do not
approve a compensation proposal of the board of directors, the board of directors must prepare a new proposal, taking into account all
relevant factors, and submit the new proposal for approval by the same general meeting of shareholders at a subsequent extraordinary general
meeting of shareholders or the next annual general meeting of shareholders.
In addition to fixed compensation, members of the board of directors
and the executive committee may be paid variable compensation depending on the achievement of certain performance criteria. The performance
criteria may include individual targets, targets of the Company or parts thereof and targets in relation to the market, other companies
or comparable benchmarks, taking into account the position and level of responsibility of the recipient of the variable compensation.
The board of directors or, where delegated to it, the compensation committee shall determine the relative weight of the performance criteria
and the respective target values.
Compensation may be paid or granted in the form of cash, shares, financial
instruments, in kind, or in the form of other types of benefits. The board of directors or, where delegated to it, the compensation committee
shall determine grant, vesting, exercise, restriction and forfeiture conditions.
Borrowing Powers
Neither Swiss law nor our articles of association restrict our power
to borrow and raise funds. The decision to borrow funds is made by or under the direction of our board of directors and no approval by
the shareholders is required in relation to any such borrowing.
Repurchases of Shares and Purchases of Own Shares
The Code of Obligations limits our ability to repurchase and hold our
own shares. We and our subsidiaries may repurchase shares only to the extent that (i) we have freely distributable reserves in the
amount of the purchase price and (ii) the aggregate par value of all shares held by us does not exceed 10% of our share capital.
Pursuant to Swiss law, where shares are acquired in connection with a transfer restriction set out in the articles of association, the
foregoing upper limit is 20%. If we own shares that exceed the threshold of 10% of our share capital, the excess must be sold or cancelled
by means of a capital reduction within two years.
Shares held by us or our subsidiaries are not entitled to vote at the
general meeting of shareholders but are entitled to the economic benefits applicable to the shares generally, including dividends and
pre-emptive subscription rights in the case of share capital increases.
In addition, selective share repurchases are only permitted under certain
circumstances. Within these limitations, as is customary for Swiss corporations, we may, subject to applicable law, purchase and sell
our own shares from time to time in order to meet imbalances of supply
and demand, to provide liquidity and to even-out variances in the market price of shares.
Notification and Disclosure of Substantial Share Interests
The disclosure obligations generally applicable to shareholders of Swiss
corporations under the Federal Act on Financial Market Infrastructures and Market Conduct in Securities and Derivatives Trading, or the
Financial Market Infrastructure Act (the “FMIA”), do not apply to us since our shares are not listed on a Swiss exchange.
Pursuant to Article 663c of the Code of Obligations, Swiss corporations
whose shares are listed on a stock exchange must disclose their significant shareholders and their shareholdings in the notes to their
statutory annual financial statements, to the extent that this information is known or ought to be known. Significant shareholders are
defined as shareholders and groups of shareholders linked through voting rights who hold more than 5% of all voting rights.
Mandatory Bid Rules
The obligation of any person or group of persons that acquires more
than one third of a company’s voting rights to submit a cash offer for all the outstanding listed equity securities of the relevant
company at a minimum price pursuant to the FMIA does not apply to us since our shares are not listed on a Swiss exchange.
Stock Exchange Listing
Our ordinary shares are listed on Nasdaq under the symbol “SOPH.”
Transfer Agent and Registrar of Shares
Our share register is kept by Computershare Trust Company, N.A., which
acts as transfer agent and registrar. The share register reflects only record owners of our shares. Swiss law does not recognize fractional
share interests.
Comparison of Swiss law and Delaware law
The Swiss laws applicable to Swiss corporations and their shareholders
differ from laws applicable to U.S. corporations and their shareholders. The following table summarizes significant differences in
shareholder rights between the provisions of the Code of Obligations and the Swiss Ordinance against excessive compensation in listed
stock corporations (Ordonnance contre les rémunérations abusives dans les sociétés anonymes cotées
en bourse) (the “OAEC”) applicable to our Company and the Delaware General Corporation Law applicable to companies incorporated
in Delaware and their shareholders. Please note that this is only a general summary of certain provisions applicable to companies in Delaware.
Certain Delaware companies may be permitted to exclude certain of the provisions summarized below in their charter documents.
DELAWARE CORPORATE LAW |
SWISS CORPORATE LAW |
Mergers and similar arrangements |
Under the Delaware General Corporation Law, with certain exceptions, a merger, consolidation, sale, lease or transfer of all or substantially all of the assets of a corporation must be approved by the board of directors and a majority of the outstanding shares entitled to vote thereon. A shareholder of a Delaware corporation participating in certain major corporate transactions may, under |
Under Swiss law, with certain exceptions, a merger
or a demerger of the corporation or a sale of all or substantially all of the assets of a corporation must be approved by two-thirds
of the voting rights represented at the respective general meeting of shareholders as well as the absolute majority of the par value
of shares represented at such general |
DELAWARE CORPORATE LAW |
SWISS CORPORATE LAW |
certain circumstances, be entitled to appraisal rights pursuant to which such shareholder may receive cash in the amount of the fair value of the shares held by such shareholder (as determined by a court) in lieu of the consideration such shareholder would otherwise receive in the transaction. The Delaware General Corporation Law also provides that a parent corporation, by resolution of its board of directors, may merge with any subsidiary, of which it owns at least 90.0% of each class of capital stock without a vote by the shareholders of such subsidiary. Upon any such merger, dissenting shareholders of the subsidiary would have appraisal rights. |
meeting of shareholders. A shareholder of a Swiss corporation participating in a statutory merger or demerger pursuant to the Swiss Merger Act (Loi sur la fusion) can file a lawsuit against the surviving company. If the consideration is deemed “inadequate,” such shareholder may, in addition to the consideration (be it in shares or in cash) receive an additional amount to ensure that such shareholder receives the fair value of the shares held by such shareholder. Swiss law also provides that if the merger agreement provides only for a compensation payment, at least 90.0% of all members in the transferring legal entity, who are entitled to vote, shall approve the merger agreement. |
Shareholders’ suits |
Class actions and derivative actions generally are available to shareholders of a Delaware corporation for, among other things, breach of fiduciary duty, corporate waste and actions not taken in accordance with applicable law. In such actions, the court has discretion to permit the winning party to recover attorneys’ fees incurred in connection with such action. |
Class actions and derivative actions as such are not available under Swiss law. Nevertheless, certain actions may have a similar effect. A shareholder is entitled to bring suit against directors, officers or liquidators for breach of their duties and claim the payment of the company’s losses or damages to the corporation and, in some cases, to the individual shareholder. Likewise, an appraisal lawsuit won by a shareholder may indirectly compensate all shareholders. In addition, to the extent that U.S. laws and regulations provide a basis for liability and U.S. courts have jurisdiction, a class action may be available. |
|
Under Swiss law, the winning party is generally entitled to recover a limited amount of attorneys’ fees incurred in connection with such action. The court has discretion to permit the shareholder who lost the lawsuit to recover attorneys’ fees incurred to the extent that he or she acted in good faith. |
|
Shareholder vote on board and management compensation |
Under the Delaware General Corporation Law, the board of directors has the authority to fix the compensation of directors, unless otherwise restricted by the certificate of incorporation or bylaws. |
Pursuant to the OAEC, the general meeting of shareholders has the non-transferable right, amongst others, to vote separately and bindingly on the aggregate amount of compensation of the members of the board of directors, of the executive committee and of the advisory boards. |
|
DELAWARE CORPORATE LAW |
SWISS CORPORATE LAW |
Annual vote on board renewal |
Unless directors are elected by written consent in lieu of an annual
meeting, directors are elected in an annual meeting of shareholders on a date and at a time designated by or in the manner provided in
the bylaws. Re-election is possible.
Classified boards are permitted.
|
The general meeting of shareholders elects the members of the board of directors, the chairperson of the board of directors and the members of the compensation committee individually and annually for a term of office until the end of the following general meeting of shareholders. Re-election is possible. |
Indemnification of directors and executive officers and limitation of liability |
The Delaware General Corporation Law provides that a certificate of
incorporation may contain a provision eliminating or limiting the personal liability of directors (but not other controlling persons)
of the corporation for monetary damages for breach of a fiduciary duty as a director, except no provision in the certificate of incorporation
may eliminate or limit the liability of a director for
·
any
breach of a director’s duty of loyalty to the corporation or its shareholders
· acts
or omissions not in good faith or which involve intentional misconduct or a knowing violation of law;
· statutory
liability for unlawful payment of dividends or unlawful share purchase or redemption; or
· any
transaction from which the director derived an improper personal benefit.
A Delaware corporation may indemnify any person who was or is a party
or is threatened to be made a party to any proceeding, other than an action by or on behalf of
the corporation, because the person is or was a director or officer,
against liability incurred in connection with the proceeding if the director or officer acted in good faith and in a manner reasonably
believed to be in, or not opposed to, the best interests of the corporation; and the director or officer, with respect to any criminal
action or proceeding, had no reasonable cause to believe his or her conduct was unlawful.
Unless ordered by a court, any foregoing indemnification is subject
to a determination
|
Under Swiss corporate law, an indemnification by the corporation of
a director or member of the executive committee in relation to potential personal liability is not effective to the extent the director
or member of the executive committee intentionally or negligently violated his or her corporate duties towards the corporation (certain
views advocate that at least a grossly negligent violation is required to exclude the indemnification). Furthermore, the general meeting
of shareholders may discharge (release) the directors and members of the executive committee from liability for their conduct to the extent
the respective facts are known to shareholders. Such discharge is effective only with respect to claims of the company and of those shareholders
who approved the discharge or who have since acquired their shares in full knowledge of the discharge. Most violations of corporate law
are regarded as violations of duties towards the corporation rather than towards the shareholders. In addition, indemnification of other
controlling persons is not permitted under Swiss corporate law, including shareholders of the corporation.
The articles of association of a Swiss corporation may also set forth
that the corporation shall indemnify and hold harmless, to the extent permitted by the law, the directors and executive managers out of
assets of the corporation against threatened, pending or completed actions.
Also, a corporation may enter into and pay for directors’ and
officers’ liability
|
DELAWARE CORPORATE LAW |
SWISS CORPORATE LAW |
that the director or officer has met the applicable standard of conduct:
·
by a
majority vote of the directors who are not parties to the proceeding, even though less than a quorum;
· by a
committee of directors designated by a majority vote of the eligible directors, even though less than a quorum;
· by independent
legal counsel in a written opinion if there are no eligible directors or if the eligible directors so direct; or
· by the
shareholders.
Moreover, a Delaware corporation may not indemnify a director or officer
in connection with any proceeding in which the director or officer has been adjudged to be liable to the corporation unless and only to
the extent that the court determines that, despite the adjudication of liability but in view of all the circumstances of the case, the
director or officer is fairly and reasonably entitled to indemnity for those expenses which the court deems proper.
|
insurance, which may cover negligent acts as well. |
Directors’ fiduciary duties |
A director of a Delaware corporation has a fiduciary duty to the
corporation and its shareholders. This duty has two components:
·
the duty of care; and
·
the
duty of loyalty.
The duty of care requires that a director act in good faith, with the
care that an ordinarily prudent person would exercise under similar circumstances. Under this
duty, a director must inform himself or herself of, and disclose to
shareholders, all material information reasonably available regarding a significant transaction.
The duty of loyalty requires that a director act in a manner he or she
reasonably believes to be in the best interests of the corporation. He or she must not use his or her corporate position for personal
gain or advantage. This duty prohibits self-dealing by a director and mandates that the best interest of the corporation and its shareholders
take precedence over any interest possessed by a director, officer or controlling shareholder and not shared by the shareholders generally.
In general, actions of a director are presumed to have been made on an informed basis, in good faith and in the honest belief that the
action taken was in the best interests of the corporation. However, this presumption may be rebutted by evidence of a breach of one of
the fiduciary duties.
Should such evidence be presented concerning a transaction by a
director, a director must prove the procedural fairness of the transaction and that the transaction was of fair value to the
corporation. |
The board of directors of a Swiss corporation manages the business
of the corporation, unless responsibility for such management has been duly delegated to the executive committee based on organizational
rules. However, there are several non-transferable duties of the board of directors:
·
the
overall management of the corporation and the issuing of all necessary directives;
·
determination
of the corporation’s organization;
·
the
organization of the accounting, financial control and financial planning systems as required for management of the corporation;
·
the
appointment and dismissal of persons entrusted with managing and representing the corporation;
·
overall
supervision of the persons entrusted with managing the corporation, in particular with regard to compliance with the law, articles of
association, operational regulations and directives;
·
compilation
of the annual report, preparation for the general meeting of the shareholders, the compensation report and implementation of its resolutions;
and
·
notification
of the court in the event that the company is over-indebted.
The members of the board of directors must perform their duties with
all due diligence and safeguard the interests of the corporation in good faith. They must afford the shareholders equal treatment in equal
circumstances.
The duty of care requires that a director act in good faith, with the
care that an ordinarily prudent director would exercise under like circumstances.
The duty of loyalty requires that a director safeguard the interests
of the corporation and requires that directors act in the interest of the corporation and, if necessarily, put aside their own interests.
If there is a risk of a conflict of interest, the board of directors must take appropriate measures to ensure that the interests of the
company are duly taken into account.
The burden of proof for a violation of these duties is with the
corporation or with the shareholder bringing a suit against the director. |
DELAWARE CORPORATE LAW |
SWISS CORPORATE LAW |
Shareholder action by written consent |
A Delaware corporation may, in its certificate of incorporation, eliminate the right of shareholders to act by written consent. |
Shareholders of a Swiss corporation may only exercise their voting rights in a general meeting of shareholders and may not act by written consents . The articles of association must allow for (independent) proxies to be present at a general meeting of shareholders. The instruction of such (independent) proxies may occur in writing or electronically. |
A shareholder of a Delaware corporation has the right to put any proposal before the annual meeting of shareholders, provided it complies with the notice provisions in the governing documents. A special meeting may be called by the board of directors or any other person authorized to do so in the governing documents, but shareholders may be precluded from calling special meetings. |
At any general meeting of shareholders any shareholder may put
proposals to the meeting if the proposal is part of an agenda item. No resolution may be taken on proposals relating to the agenda items
that were not duly notified. Unless the articles of association provide for a lower threshold or for additional shareholders’ rights:
shareholders
together representing at least 10% of the share capital may demand that a general meeting of shareholders be called for specific agenda
items and specific proposals; and shareholders together representing shares with a par value of at least CHF 1.0 million or 10%
of the share capital, whichever is lower, may demand that an agenda item including a specific proposal be put on the agenda for a scheduled
general meeting of shareholders, provided such request is made with appropriate lead time. |
|
Any shareholder can propose candidates for election as directors or
make other proposals within the scope of an agenda item without prior written notice.
In addition, any shareholder is entitled, at a general meeting
of shareholders and without advance notice, to (i) request information from the board of directors on the affairs of the company
(note, however, that the right to obtain such information is limited), (ii) request information from the auditors on the methods and
results of their audit, (iii) request that the general meeting of shareholders resolve to convene an extraordinary general meeting,
or (iv) request that the general meeting of shareholders resolve to appoint an examiner to carry out a special examination (“contrôle
spécial”). |
|
DELAWARE CORPORATE LAW |
SWISS CORPORATE LAW |
Under the Delaware General Corporation Law, cumulative voting for elections
of directors is not permitted unless the corporation’s certificate of incorporation provides for it.
|
Cumulative voting is not permitted under Swiss corporate law. Pursuant
to Swiss law, shareholders can vote for each proposed candidate, but they are not allowed to cumulate their votes for single candidates.
An annual individual election of (i) all members of the board of directors, (ii) the chairperson of the board of directors,
(iii) the members of the compensation committee, (iv) the election of the independent proxy for a term of
office of one year (i.e., until the following annual general meeting
of shareholders), as well as the vote on the aggregate amount of compensation of the members of the board of directors, of the executive
committee and of the members of any advisory board, is mandatory for listed companies. Re-election is permitted. |
|
A Delaware corporation with a classified board may be removed only for cause with the approval of a majority of the outstanding shares entitled to vote, unless the certificate of incorporation provides otherwise. |
A Swiss corporation may remove, with or without cause, any director at any time with a resolution passed by a majority of the shares represented at a general meeting of shareholders. The articles of association may require the approval by a supermajority of the shares represented at a meeting for the removal of a director. |
|
Transactions with interested shareholders |
The Delaware General Corporation Law generally prohibits a Delaware corporation from engaging in certain business combinations with an “interested shareholder” for three years following the date that such person becomes an interested shareholder. An interested shareholder generally is a person or group who or which owns or owned 15.0% or more of the corporation’s outstanding voting shares within the past three years. |
No such rule applies to a Swiss corporation. |
|
Unless the board of directors of a Delaware corporation approves the proposal to dissolve, dissolution must be approved by shareholders holding 100.0% of the total voting power of the corporation. Only if the dissolution is initiated by the board of directors may it be approved by a simple majority of the corporation’s outstanding shares. Delaware law allows a Delaware corporation to include in its certificate of incorporation a supermajority voting requirement in connection with dissolutions initiated by the board. |
A dissolution of a Swiss corporation requires the approval by two-thirds of the voting rights represented at the respective general meeting of shareholders as well as the absolute majority of the par value of shares represented at such general meeting of shareholders. The articles of association may increase the voting thresholds required for such a resolution. |
|
Variation of rights of shares |
DELAWARE CORPORATE LAW |
SWISS CORPORATE LAW |
A Delaware corporation may vary the rights of a class of shares with the approval of a majority of the outstanding shares of such class, unless the certificate of incorporation provides otherwise. |
The general meeting of shareholders of a Swiss corporation may resolve that preference shares be issued or that existing shares be converted into preference shares with a resolution passed by a majority of the shares represented at the general meeting of shareholders. Where a company has |
|
issued preference shares, further preference shares conferring preferential
rights over the existing preference shares may be issued only with the consent of both a special meeting of the adversely affected holders
of the existing preference shares and of a general meeting of all shareholders, unless otherwise provided in the articles of association.
Shares with preferential voting rights are not regarded as preference
shares for these purposes.
|
|
Amendment of governing documents |
A Delaware corporation’s governing documents may be amended with the approval of a majority of the outstanding shares entitled to vote, unless the certificate of incorporation provides otherwise. |
The articles of association of a Swiss corporation may be amended with
a resolution passed by a majority of the shares represented at a general meeting of shareholders, unless otherwise provided in the articles
of association.
There are a number of resolutions, such as an amendment of the stated
purpose of the corporation, the introduction of authorized and conditional capital and the introduction of shares with preferential voting
rights that require the approval by two-thirds of the votes and an absolute majority of the par value of the shares represented at such
general meeting of shareholders. The articles of association may increase these voting thresholds.
|
|
|
Inspection of books and records |
Shareholders of a Delaware corporation, upon written demand under oath stating the purpose thereof, have the right during the usual hours for business to inspect for any proper purpose and to obtain copies of list(s) of shareholders and other books and records of the corporation and its subsidiaries, if any, to the extent the books and records of such subsidiaries are available to the corporation. |
Shareholders of a Swiss corporation may only inspect books and records if the general meeting of shareholders or the board of directors approved such inspection. The information may be refused where providing it would jeopardize the corporation’s trade secrets or other interests warranting protection. A shareholder is only entitled to receive information to the extent required to exercise his or her rights as a shareholder, subject to the interests of the corporation. A shareholder’s right to inspect the share register is limited to the right to inspect his or her own entry in the share register. |
|
|
DELAWARE CORPORATE LAW |
SWISS CORPORATE LAW |
The board of directors may approve a dividend without shareholder approval.
Subject to any restrictions contained in its certificate of incorporation, the board may declare and pay dividends upon the shares of
its capital stock either:
·
out of its surplus; or
·
in case
there is no such surplus, out of its net profits for the fiscal year in which the dividend is declared and/or the preceding fiscal year.
Shareholder approval is required to authorize capital stock in excess
of that provided in the charter. Directors may issue authorized shares without shareholder approval.
|
Dividend payments are subject to the approval of the general meeting
of shareholders. The board of directors may propose to shareholders that a dividend shall be paid but cannot itself authorize the distribution
Payments out of a corporation’s share capital (in other words,
the aggregate par value of the corporation’s registered share capital) in the form of dividends are not allowed and may be made
only by way of a share capital reduction. Dividends may be paid only from the profits of the previous business year or brought forward
from previous business years or if the corporation has distributable reserves, each as evidenced by the corporation’s audited stand-alone
statutory balance sheet prepared pursuant to Swiss law and after allocations to reserves required by Swiss law and the articles of association
have been deducted.
|
Creation and issuance of new shares |
All creation of shares require the board of directors to adopt a resolution or resolutions, pursuant to authority expressly vested in the board of directors by the provisions of the company’s certificate of incorporation. |
All creation of shares require a shareholders’ resolution. The creation of authorized or contingent share capital requires at least two-thirds of the voting rights represented at the general meeting of shareholders and an absolute majority of the par value of shares represented at such meeting. The board of directors may issue shares out of the authorized share capital during a period of up to two years. Shares are created and issued out of contingent share capital through the exercise of options or of conversion rights that the board of director may grant in relation to, e.g., debt instruments or employees. |
DESCRIPTION OF DEBT SECURITIES
We may issue debt securities, which may be secured or unsecured and
may be exchangeable for and/or convertible into other securities, including our ordinary shares. The debt securities will be issued under
one or more separate indentures between us and a designated trustee. The terms of each series of debt securities being offered, including
the terms, if any, on which a series of debt securities may be convertible into or exchangeable for other securities, and the material
terms of the indenture will be set forth in the applicable prospectus supplement.
DESCRIPTION OF WARRANTS
We may issue warrants to purchase our debt or equity securities. The
warrants may be issued independently or together with any other securities and may be attached to, or separate from, such securities.
Each series of warrants will be issued under a separate warrant agreement to be entered into between us and a warrant agent. The terms
of any warrants being offered and a description of the material provisions of the applicable warrant agreement will be set forth in the
applicable prospectus supplement.
DESCRIPTION OF SUBSCRIPTION RIGHTS
We may issue subscription rights to purchase our securities. The subscription
rights may be issued independently or together with any other securities, may be attached to, or separate from, such securities and may
or may not be transferable by the shareholder receiving the subscription rights. In connection with any offering of subscription rights,
we may enter into a standby arrangement with one or more underwriters or other purchasers pursuant to which the underwriters or other
purchasers may be required to purchase any unsubscribed securities after such offering. The terms of any subscription rights being offered
will be set forth in the applicable prospectus supplement.
If fewer than all of the subscription rights issued in any rights offering
are exercised, we may offer any unsubscribed securities directly to persons other than shareholders, to or through agents, underwriters
or dealers or through a combination of such methods, including pursuant to standby arrangements, as described in the applicable prospectus
supplement.
DESCRIPTION OF PURCHASE CONTRACTS
We may issue purchase contracts for the purchase or sale of debt or
equity securities issued by us or securities of third parties, a basket of such securities, an index or indices or such securities or
any combination of the above as specified in the applicable prospectus supplement, currencies or commodities.
Each purchase contract will entitle the holder thereof to purchase or
sell, and obligate us to sell or purchase, on specified dates, such securities, currencies or commodities at a specified purchase price,
which may be based on a formula, all as set forth in the applicable prospectus supplement. A purchase by us or any of our subsidiaries
of ordinary shares pursuant to any such purchase contract shall be subject to certain restrictions under Swiss law that generally apply
to a repurchase of shares. We may, however, satisfy our obligations, if any, with respect to any purchase contract by delivering the cash
value of such purchase contract or the cash value of the property otherwise deliverable or, in the case of purchase contracts on underlying
currencies, by delivering the underlying currencies, as set forth in the applicable prospectus supplement. The applicable prospectus supplement
will also specify the methods by which the holders may purchase or sell such securities, currencies or commodities and any acceleration,
cancellation or termination provisions or other provisions relating to the settlement of a purchase contract.
The purchase contracts may require us to make periodic payments to the
holders thereof or vice versa, which payments may be deferred to the extent set forth in the applicable prospectus supplement, and those
payments may be unsecured or prefunded on some basis. The purchase contracts may require the holders thereof to secure their obligations
in a specified manner to be described in the applicable
prospectus supplement. Alternatively, purchase contracts may require
holders to satisfy their obligations thereunder when the purchase contracts are issued. Our obligation to settle such pre-paid purchase
contracts on the relevant settlement date may constitute indebtedness. Accordingly, pre-paid purchase contracts will be issued under an
indenture.
DESCRIPTION OF UNITS
As specified in the applicable prospectus supplement, we may issue units
consisting of one or more warrants, debt securities, ordinary shares, purchase contracts or any combination of such securities. The terms
of the units and the securities comprising such units and the material terms of the unit agreement will be set forth in the applicable
prospectus supplement.
FORMS OF SECURITIES
Each debt security, warrant and unit will be represented either by a
certificate issued in definitive form to a particular investor or by one or more global securities representing the entire issuance of
securities. Certificated securities will be issued in definitive form and global securities will be issued in registered form. Definitive
securities name you or your nominee as the owner of the security, and in order to transfer or exchange these securities or to receive
payments other than interest or other interim payments, you or your nominee must physically deliver the securities to the trustee, registrar,
paying agent or other agent, as applicable. Global securities name a depositary or its nominee as the owner of the debt securities, warrants
or units represented by these global securities. The depositary maintains a computerized system that will reflect each investor’s
beneficial ownership of the securities through an account maintained by the investor with its broker/dealer, bank, trust company or other
representative, as we explain more fully below.
Registered Global Securities
We may issue registered debt securities, warrants and units in the form
of one or more fully registered global securities that will be deposited with a depositary or its nominee identified in the applicable
prospectus supplement and registered in the name of that depositary or nominee. In those cases, one or more registered global securities
will be issued in a denomination or aggregate denominations equal to the portion of the aggregate principal or face amount of the securities
to be represented by registered global securities. Unless and until it is exchanged in whole for securities in definitive registered form,
a registered global security may not be transferred except as a whole by and among the depositary for the registered global security,
the nominees of the depositary or any successors of the depositary or those nominees.
If not described below, any specific terms of the depositary arrangement
with respect to any securities to be represented by a registered global security will be described in the prospectus supplement relating
to those securities. We anticipate that the following provisions will apply to all depositary arrangements.
Ownership of beneficial interests in a registered global security will
be limited to persons, called participants, that have accounts with the depositary or persons that may hold interests through participants.
Upon the issuance of a registered global security, the depositary will credit, on its book-entry registration and transfer system, the
participants’ accounts with the respective principal or face amounts of the securities beneficially owned by the participants. Any
dealers, underwriters or agents participating in the distribution of the securities will designate the accounts to be credited. Ownership
of beneficial interests in a registered global security will be shown on, and the transfer of ownership interests will be effected only
through, records maintained by the depositary, with respect to interests of participants, and on the records of participants, with respect
to interests of persons holding through participants. The laws of some states may require that some purchasers of securities take physical
delivery of these securities in definitive form. These laws may impair your ability to own, transfer or pledge beneficial interests in
registered global securities.
So long as the depositary, or its nominee, is the registered owner of
a registered global security, that depositary or its nominee, as the case may be, will be considered the sole owner or holder of the
securities represented by the registered global security for all purposes
under the applicable indenture, warrant agreement or unit agreement. Except as described below, owners of beneficial interests in a registered
global security will not be entitled to have the securities represented by the registered global security registered in their names, will
not receive or be entitled to receive physical delivery of the securities in definitive form and will not be considered the owners or
holders of the securities under the applicable indenture, warrant agreement or unit agreement. Accordingly, each person owning a beneficial
interest in a registered global security must rely on the procedures of the depositary for that registered global security and, if that
person is not a participant, on the procedures of the participant through which the person owns its interest, to exercise any rights of
a holder under the applicable indenture, warrant agreement or unit agreement. We understand that under existing industry practices, if
we request any action of holders or if an owner of a beneficial interest in a registered global security desires to give or take any action
that a holder is entitled to give or take under the applicable indenture, warrant agreement or unit agreement, the depositary for the
registered global security would authorize the participants holding the relevant beneficial interests to give or take that action, and
the participants would authorize beneficial owners owning through them to give or take that action or would otherwise act upon the instructions
of beneficial owners holding through them.
Principal, premium, if any, and interest payments on debt securities,
and any payments to holders with respect to warrants or units, represented by a registered global security registered in the name of a
depositary or its nominee will be made to the depositary or its nominee, as the case may be, as the registered owner of the registered
global security. None of the Company, the trustees, the warrant agents, the unit agents or any other agent of the Company, agent of the
trustees or agent of the warrant agents or unit agents will have any responsibility or liability for any aspect of the records relating
to payments made on account of beneficial ownership interests in the registered global security or for maintaining, supervising or reviewing
any records relating to those beneficial ownership interests.
We expect that the depositary for any of the securities represented
by a registered global security, upon receipt of any payment of principal, premium, interest or other distribution of underlying securities
or other property to holders on that registered global security, will immediately credit participants’ accounts in amounts proportionate
to their respective beneficial interests in that registered global security as shown on the records of the depositary. We also expect
that payments by participants to owners of beneficial interests in a registered global security held through participants will be governed
by standing customer instructions and customary practices, as is now the case with the securities held for the accounts of customers in
bearer form or registered in “street name,” and will be the responsibility of those participants.
If the depositary for any of these securities represented by a registered
global security is at any time unwilling or unable to continue as depositary or ceases to be a clearing agency registered under the Exchange
Act, and a successor depositary registered as a clearing agency under the Exchange Act is not appointed by us within 90 days, we will
issue securities in definitive form in exchange for the registered global security that had been held by the depositary. Any securities
issued in definitive form in exchange for a registered global security will be registered in the name or names that the depositary gives
to the relevant trustee, warrant agent, unit agent or other relevant agent of ours or theirs. It is expected that the depositary’s
instructions will be based upon directions received by the depositary from participants with respect to ownership of beneficial interests
in the registered global security that had been held by the depositary.
PLAN OF DISTRIBUTION
We may sell the securities in one or more of the following ways (or
in any combination) from time to time:
| · | through underwriters or dealers; |
| · | directly to a limited number of purchasers or to a single purchaser; |
| · | in “at the market offerings,” within the meaning of Rule 415(a)(4) of the Securities Act, to or through a market maker
or into an existing trading market on an exchange or otherwise; |
| · | through any other method permitted by applicable law and described in the applicable prospectus supplement. |
The prospectus supplement will state the terms of the offering of the
securities, including:
| · | the name or names of any underwriters, dealers or agents; |
| · | the purchase price of such securities and the proceeds to be received by us, if any; |
| · | any underwriting discounts or agency fees and other items constituting underwriters’ or agents’ compensation; |
| · | any public offering price; |
| · | any discounts or concessions allowed or reallowed or paid to dealers; and |
| · | any securities exchanges on which the securities may be listed. |
Any public offering price and any discounts or concessions allowed or
reallowed or paid to dealers may be changed from time to time.
If underwriters are used in the sale, the securities will be acquired
by the underwriters for their own account and may be resold from time to time in one or more transactions, including:
| · | negotiated transactions; |
| · | at a fixed public offering price or prices, which may be changed; |
| · | at market prices prevailing at the time of sale; |
| · | at prices related to prevailing market prices; or |
Unless otherwise stated in a prospectus supplement, the obligations
of the underwriters to purchase any securities will be conditioned on customary closing conditions and the underwriters will be obligated
to purchase all of such series of securities, if any are purchased.
The securities may be sold through agents from time to time. The prospectus
supplement will name any agent involved in the offer or sale of the securities and any commissions paid to them. Generally, any agent
will be acting on a best efforts basis for the period of its appointment.
Sales to or through one or more underwriters or agents in at-the-market
offerings will be made pursuant to the terms of a distribution agreement with the underwriters or agents. Such underwriters or agents
may act on an agency basis or on a principal basis. During the term of any such agreement, shares may be
sold on a daily basis on any stock exchange, market or trading facility
on which the ordinary shares are traded, in privately negotiated transactions or otherwise as agreed with the underwriters or agents.
The distribution agreement will provide that any ordinary share sold will be sold at negotiated prices or at prices related to the then
prevailing market prices for our ordinary shares. Therefore, exact figures regarding proceeds that will be raised or commissions to be
paid cannot be determined at this time and will be described in a prospectus supplement. Pursuant to the terms of the distribution agreement,
we may also agree to sell, and the relevant underwriters or agents may agree to solicit offers to purchase, blocks of our ordinary shares
or other securities. The terms of each such distribution agreement will be described in a prospectus supplement.
We may authorize underwriters, dealers or agents to solicit offers by
certain purchasers to purchase the securities at the public offering price set forth in the prospectus supplement pursuant to delayed
delivery contracts providing for payment and delivery on a specified date in the future. The contracts will be subject only to those conditions
set forth in the prospectus supplement, and the prospectus supplement will set forth any commissions paid for solicitation of these contracts.
Underwriters and agents may be entitled under agreements entered into
with us to indemnification by us against certain civil liabilities, including liabilities under the Securities Act, or to contribution
with respect to payments which the underwriters or agents may be required to make.
The prospectus supplement may also set forth whether or not underwriters
may over-allot or effect transactions that stabilize, maintain or otherwise affect the market price of the securities at levels above
those that might otherwise prevail in the open market, including, for example, by entering stabilizing bids, effecting syndicate covering
transactions or imposing penalty bids.
Underwriters and agents may be customers of, engage in transactions
with, or perform services for us and our affiliates in the ordinary course of business.
Each series of securities will be a new issue of securities and will
have no established trading market, other than our ordinary shares, which are listed on the Nasdaq. Any underwriters to whom securities
are sold for public offering and sale may make a market in the securities, but such underwriters will not be obligated to do so and may
discontinue any market making at any time without notice. The securities, other than our ordinary shares, may or may not be listed on
a national securities exchange.
EXPENSES OF THE OFFERING
The following table sets forth the expenses (other than underwriting
discounts and commissions or agency fees and other items constituting underwriters’ or agents’ compensation, if any) expected
to be incurred by us in connection with a possible offering of securities registered under this registration statement:
Expenses |
|
Amount |
|
SEC registration fee |
|
$ |
18,540 |
|
FINRA filing fee |
|
|
30,500 |
|
Printing and engraving expenses |
|
|
(1) |
|
Legal fees and expenses |
|
|
(1) |
|
Accounting fees and expenses |
|
|
(1) |
|
Miscellaneous costs |
|
|
(1) |
|
Total |
|
$ |
(1) |
|
| (1) | These fees and expenses depend on the securities offered and the number of issuances, and accordingly cannot be estimated at this
time and will be reflected in the applicable prospectus supplement. |
LEGAL MATTERS
The validity of certain securities and certain other matters with respect
to Swiss law will be passed upon for us by Homburger AG, Zurich, Switzerland. The validity of certain securities and certain matters with
respect to U.S. federal and New York State law will be passed upon for us by Davis Polk & Wardwell LLP, New York, New York. Any underwriters,
dealers or agents will be advised by their own legal counsel concerning issues relating to any offering.
EXPERTS
The financial statements incorporated in this Prospectus by reference
to the Annual Report on Form 20-F for the year ended December 31, 2021 have been so incorporated in reliance on the report of PricewaterhouseCoopers
SA, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. PricewaterhouseCoopers
SA is a member of EXPERTsuisse — Swiss Expert Association for Audit, Tax, and Fiduciary.
ENFORCEMENT OF JUDGMENTS
We are organized under the laws of Switzerland and our registered office
and domicile is located in Saint-Sulpice, Switzerland. Moreover, a number of our directors and executive officers are not residents of
the United States, and all or a substantial portion of the assets of such persons are located outside the United States. As a result,
it may not be possible for investors to effect service of process within the United States upon us or upon such persons or to enforce
against them judgments obtained in U.S. courts, including judgments in actions predicated upon the civil liability provisions of the federal
securities laws of the United States. We have been advised by our Swiss counsel that there is doubt as to the enforceability in Switzerland
of original actions, or in actions for enforcement of judgments of U.S. courts, of civil liabilities to the extent solely predicated upon
the federal and state securities laws of the United States. Original actions against persons in Switzerland based solely upon the U.S.
federal or state securities laws are governed, among other things, by the principles set forth in the Swiss Federal Act on Private International
Law (the “PILA”). This statute provides that the application of provisions of non-Swiss law by the courts in Switzerland shall
be precluded if the result would be incompatible with Swiss public policy. Also, mandatory provisions of Swiss law may be applicable regardless
of any other law that would otherwise apply.
Switzerland and the United States do not have a treaty providing for
reciprocal recognition of and enforcement of judgments in civil and commercial matters. The recognition and enforcement of a judgment
of the courts of the United States in Switzerland is governed by the principles set forth in the PILA. This statute provides in principle
that a judgment rendered by a non-Swiss court may be enforced in Switzerland only if:
| · | the non-Swiss court had jurisdiction pursuant to the PILA; |
| · | the judgment of such non-Swiss court has become final and non-appealable; |
| · | the judgment does not contravene Swiss public policy; |
| · | the court procedures and the service of documents leading to the judgment were in accordance with the due process of law; and |
| · | no proceeding involving the same position and the same subject matter was first brought in Switzerland, or adjudicated in Switzerland,
or was earlier adjudicated in a third state and this decision is recognizable in Switzerland. |
WHERE YOU CAN FIND MORE INFORMATION
We are subject to the informational requirements of the Exchange Act.
Accordingly, we are required to file reports and other information with the SEC, including annual reports on Form 20-F and reports on
Form 6-K. The SEC maintains an Internet site at www.sec.gov that contains reports, proxy and information statements and other information
we have filed electronically with the SEC. As a foreign private issuer, we are exempt under the Exchange Act from, among other things,
the rules prescribing the furnishing and content of proxy statements, and our executive officers, directors and principal shareholders
are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. In addition, we
are not required under the Exchange Act to file periodic reports and financial statements with the SEC as frequently or as promptly as
U.S. companies whose securities are registered under the Exchange Act.
We have filed with the SEC a “shelf” registration statement
(including amendments and exhibits to the registration statement) on Form F-3 under the Securities Act. This prospectus, which is part
of the registration statement, does not contain all of the information set forth in the registration statement and the exhibits and schedules
to the registration statement. We have omitted parts of the registration statement in accordance with the rules and regulations of the
SEC. For more detail about us and the securities that may be offered by this prospectus, you may examine the registration statement on
Form F-3 and the exhibits filed with it at the website provided in the previous paragraph.
We maintain a corporate website at www.sophiagenetics.com. The
reference to our website is an inactive textual reference only, and information contained therein or connected thereto is not incorporated
into this prospectus or the registration statement of which it forms a part.
INFORMATION INCORPORATED BY REFERENCE
The rules of the SEC allow us to incorporate by reference information
in this prospectus, which means that we disclose important information to you by referring you to another document filed separately with
the SEC. The information incorporated by reference in this prospectus is considered to be a part of this prospectus. Any statement made
in this prospectus or in a document incorporated or deemed to be incorporated by reference in this prospectus will be deemed to be modified
or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus or in any other subsequently
filed document that is also incorporated or deemed to be incorporated by reference in this prospectus modifies or supersedes that statement.
Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this prospectus.
This prospectus incorporates by reference the documents listed below:
| · | our Report on Form 6-K filed with the SEC on March 15, 2022 (only with respect to Exhibit 99.4 thereto (other than the Report of the
Statutory Auditor and Section 4 (Equity and Equity-Linked Instruments Held by Members of the Board of Directors and the Executive Committee))),
May 10, 2022 (only with respect to Exhibits 99.1 and 99.2 thereto), June 15, 2022 (Film No. 221017967) (other than Exhibit 99.2 thereto)
and August 9, 2022 (only with respect to Exhibits 99.1 and 99.2 thereto); and |
All subsequent annual reports on Form 20-F, Form 40-F or Form 10-K that
we file with the SEC and all subsequent filings on Forms 10-Q and 8-K filed by us with the SEC pursuant to the Exchange Act (excluding,
in each case, any information or documents deemed to be furnished and not filed with the SEC), after the date hereof and prior to the
termination or expiration of the registration statement of which this prospectus forms a part, shall be incorporated by reference. We
may incorporate by reference any reports on Form 6-K that we furnish to the SEC that we specifically identify in such form or in any applicable
prospectus supplement as being incorporated by reference into this prospectus or such prospectus supplement after the date hereof and
prior to the completion of an offering of securities under this prospectus.
You can obtain any of the filings incorporated by reference in this
prospectus through us or from the SEC through the SEC’s website at www.sec.gov. Our filings with the SEC, including our Annual
Reports on Form 20-F and Reports on Form 6-K and exhibits incorporated in and amendments to those reports, are also available free of
charge on our website (www.sophiagenetics.com) as soon as reasonably practicable after they are filed with, or furnished to, the
SEC. The reference to our website is an inactive textual reference only, and information contained therein or connected thereto is not
incorporated into this prospectus or the registration statement of which it forms a part. We will provide to each person, including any
beneficial owner, to whom this prospectus is delivered, a copy of any or all the reports or documents incorporated by reference in this
prospectus at no cost, upon written or oral request to us at the following address:
Investor Relations
SOPHiA GENETICS SA
c/o SOPHiA GENETICS, Inc.
185 Dartmouth Street Floor 5
Boston, MA 02116
SOPHiA GENETICS SA
Up to $50,000,000
Ordinary Shares
PROSPECTUS SUPPLEMENT
TD Cowen
August 8, 2023
Sophia Genetics (NASDAQ:SOPH)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024
Sophia Genetics (NASDAQ:SOPH)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024